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ABSTRACT 
 
Viral protein U (Vpu) is a versatile accessory protein of human immunodeficiency 
virus type 1 (HIV-1) and some simian immunodeficiency virus isolates. Amongst 
other functions, Vpu targets human CD4 for ubiquitination and proteasomal 
degradation. This process requires the presence of phospho-serine residues 
within the Vpu cytoplasmic domain in order to allow for the recruitment of beta-
transducin repeat-containing protein (β-TrCP) and ultimately the E3 ligase 
complex. Similarly, it has been shown that the Vpu cytoplasmic domain also 
interacts with the human CD74 cytoplasmic region. CD74, the invariant chain of 
major histocompatibility complex class II (MHCII), is involved in the presentation 
of foreign antigens to CD4+ T cells. The Vpu/CD74 interaction may prevent the 
maturation of the MCHII complex resulting in the downmodulation of cell surface 
levels of MHCII. There are several structural similarities between the human CD4 
and CD74 host proteins. Consequently, we hypothesised that HIV-1 Vpu targets 
human CD74 for proteasomal degradation through the binding of β-TrCP similar 
to that of Vpu-mediated CD4 proteasomal degradation. In view of this, this study 
aimed to delineate the binding interaction between HIV-1 Vpu and CD74 and to 
determine whether Vpu also targets CD74 for proteasomal degradation. An in 
silico homology study determined that the α-helices found within the cytoplasmic 
domains of CD4 and CD74 were similar with an RMSD of 1.437 Å. Recombinant 
Vpu::GFP fusion proteins were expressed in HEK 293T cells and purified in 
sufficient quantities and purity for use in subsequent in vitro assays. Using 
ELISAs, it was found that CD74 effectively prevented the binding of an anti-Vpu 
antibody, but not an anti-GFP antibody, to the Vpu::GFP fusion protein with an 
IC50 of 888.67 ± 130.08 nM. Further to this, using CD74 overlapping peptides of 
increasing lengths in combination with a Vpu overlapping peptide set, it was 
determined that the sequences “RIRERAEDSGNESEG” and “EDQKP” in the Vpu 
and CD74 cytoplasmic regions, respectively, contain the binding sites for this 
interaction. While the CD4 and CD74 cytoplasmic peptides yielded different 
responses after binding Vpu peptides, these two host proteins were shown to 
compete for binding to the Vpu protein. This provides evidence that steric 
hindrance has an effect on binding. Finally, total CD74 levels including cell 
membrane and intracellular fractions were significantly downregulated by Vpu at 
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24 and 48 hours (p = 0.0270 and 0.0062, respectively) as indicated by 
immunoprecipitation and flow cytometry in Vpu-transfected U937 cells. Notably, 
Vpu phosphorylation mutants (S52A and S52/56A) were unable to reduce CD74 
levels within U937 cells, indicating that CD74 is not targeted for proteasomal 
degradation. In conclusion, this study has defined the specific Vpu/CD74 binding 
site and provides novel evidence that CD74 is downregulated in the presence of 
Vpu. Moreover, CD74 is not targeted for proteasomal degradation through the 
binding of β-TrCP and the recruitment of the E3 ligase complex. These findings 
have future relevance for HIV-1 treatment and management as CD74 
downregulation is yet another mechanism by which HIV-1 impairs the host 
immune response. 
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CHAPTER ONE: LITERATURE 
REVIEW 
 
1.1 General introduction to HIV-1 accessory proteins 
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that causes 
Acquired Immune Deficiency Syndrome (AIDS). This creates a life-long infection 
through the presence of latent, perpetual HIV-1 reservoirs within CD4+ T cells 
that persist even throughout treatment with highly active antiretroviral therapy 
(HAART) (reviewed in Chun and Fauci, 1999). This disease impairs the immune 
system through the infection of cells that are vital for generating an immune 
response (reviewed in Peters and Sperber, 1999) and is characterized by a 
considerable decrease in CD4+ T cells and a grossly weakened immune system 
which then becomes incapable of dealing with other opportunistic infections 
(Komoto et al., 2003). HIV-1 has an integrated genome of approximately 9.8 
kilobases and encodes proteins that are needed for cell entry, replication and 
budding. It also contains several genes, such as vif, vpr, nef and vpu, which 
encode accessory regulatory proteins with apparent importance, that were once 
deemed “non-essential” (reviewed in Strebel, 1996; Marassi et al., 1999). 
However, it is now recognized that HIV-1 accessory proteins are indeed needed 
for replication as they are designed to be multifunctional, and counteract the 
antiviral activity of host restriction factors (reviewed in Dubé et al., 2010a).  
 
HIV-1 accessory proteins are versatile adaptor molecules that are able to connect 
viral and cellular proteins to cellular pathways, as well as regulate these 
pathways through protein-protein interactions in order to promote viral replication 
(Hussain et al., 2007). These proteins are actively involved in the establishment 
of infective persistence within the host. Decreased levels of these accessory 
proteins may lead to a significant loss in the severity of disease, as these 
accessory proteins have important functions for the disruption of host 
mechanisms that are in place to restrict the spread of HIV-1 infection (Nomaguchi 
et al., 2008). Virion infectivity factor (Vif) targets the antiviral factor apolipoprotein 
B mRNA-editing enzyme, catalytic polypeptide-like 3G (APOBEC3G) for 
proteasomal degradation, as in the absence of Vif this antiviral factor is 
incorporated into new viruses and causes an inhibition of viral DNA synthesis 
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(reviewed in Kirchhoff, 2010). Viral protein R (Vpr) is involved in numerous 
activities including the induction of cell death and activation of proviral 
transcription (reviewed in Kirchhoff, 2010). Negative factor (Nef) is reportedly the 
most functionally diverse of the accessory proteins as it functions to alter cell 
signalling pathways, and affect antigen presentation as well as gene expression 
and receptor surface expression (reviewed in Kirchhoff, 2010). Finally, viral 
protein “u” (Vpu) has also been shown to have multiple functions within the host 
cell, the most well-known being the degradation of the HIV-1 receptor, CD4, as 
well as efficient virion release (reviewed in Kirchhoff, 2010). 
 
1.2 HIV-1 Vpu 
1.2.1 Introduction to Vpu 
Many aspects of HIV-1 infection involve the host cell membranes and as such 
many membrane proteins like Vpu, are intimately involved in the spread of HIV-1 
(Marassi et al., 1999). Vpu is an important accessory protein that is found only in 
HIV-1 and a few simian immunodeficiency virus (SIV) isolates such as SIVcpz 
(chimpanzee), SIVmon (mona monkey), SIVgsn (greater spot-nosed monkey), 
SIVmus (mustached monkey) and SIVden (Dent’s mona monkey), but is not 
found within HIV-2 (reviewed in Dubé et al., 2010a). Related isolates that do not 
express a functional Vpu protein have far less severity in terms of disease 
outcome (reviewed in Leligdowicz and Rowland-Jones, 2008). Vpu is a 
conserved protein that contains a 12 residue sequence (ERAEDSGNESEG) that 
is constant through all HIV isolates that express Vpu (Myers et al., 1992; Chen at 
al., 1993). Vpu and the envelope (Env) glycoprotein are cotranslationally 
expressed from the same bicistronic mRNA that is dependent on the HIV-1 Rev 
protein, resulting in approximately equal amounts of both Vpu and Env (reviewed 
in Strebel, 1996; reviewed in Dubé et al., 2010a). Vpu is expressed in the later 
stages of infection and the cellular location of Vpu appears to depend on the 
subtype of the virus (reviewed in Dubé et al., 2010a). It is thought that Vpu 
contains two trafficking signals in the hinge region that lies between the 
transmembrane domain and the cytoplasmic domain as well as within the second 
or C-terminal α-helix (reviewed in Dubé et al., 2010a). It has been suggested that 
there are deviations in the primary sequences of these trafficking signals between 
HIV-1 subtypes which would explain why Vpu expressed from different subtypes 
is not localized within the same cellular compartments. This difference is 
demonstrated between subtype B and subtype C, where subtype B Vpu localizes 
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mainly within intracellular membranes such as the endoplasmic reticulum (ER), 
Golgi and endosomes, while subtype C Vpu is reportedly found mostly at the 
plasma membrane (reviewed in Dubé et al., 2010a). 
 
1.2.2 The structure of Vpu 
Vpu consists of 81 residues with a size of 9 kilo Daltons (kDa) and is a type I 
integral membrane protein with two distinct domains: the N-terminal 
transmembrane hydrophobic helix (residues 1-27) and two amphipathic α helices 
(residues 35-50 and 58-70 respectively) that form part of the cytoplasmic domain 
and are separated by a linker region (residues 47-58), as shown in Figure 1.1. 
The linker region contains two highly conserved serine residues, namely Ser52 
and Ser56, which are phosphorylated by casein kinase II (reviewed in Andrew 
and Strebel, 2010). It has been suggested that Vpu is not constitutively 
phosphorylated, but rather that two forms of Vpu exist within the cell, both 
unphosphorylated and phosphorylated (Belaϊdouni et al., 2007) as demonstrated 
by the schematics in Figure 1.1 A and B, respectively. 
 
 
Figure 1.1: Schematic representation of Vpu based on nuclear magnetic resonance 
(NMR) structural elucidation. This schematic shows the N-terminal region, followed by 
a relatively short transmembrane domain and the two α-helices that reside in the 
cytoplasm. The two conserved phosphorylated serine residues that are required for CD4 
degradation lie in the linker region between the two cytoplasmic helices (adapted from 
Andrew and Strebel, 2010; Dubé et al., 2010a). 
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The transmembrane and cytoplasmic domains have been shown to fold 
independently of each other (Ma et al., 2002; Hussain et al., 2007; Nomaguchi et 
al., 2008). Nuclear magnetic resonance (NMR) studies have shown that the 
transmembrane domain lies vertically within the lipid bilayer while the two 
cytoplasmic helices lie parallel to the lipid bilayer (Marassi et al., 1999). More 
recent evidence has indicated that the transmembrane domain tilts at an angle of 
approximately 6-15 degrees (Kukol and Arkin, 1999; Park et al., 2003) and that 
the linker region between the two cytoplasmic helices is largely flexible, allowing 
for the second cytoplasmic helix to move and possibly lie parallel to the first 
cytoplasmic helix (reviewed in Andrew and Strebel, 2010). The first cytoplasmic 
helix is considered to lie parallel to and be partly buried in the membrane to 
shield the hydrophobic residues, leaving the charged residues exposed. 
However, the exact conformation of Vpu may be dependent on oligomerization or 
the interaction with other host proteins (Kukol and Arkin, 1999; Lemaitre et al., 
2006; Wittlich et al., 2009; reviewed in Andrew and Strebel, 2010). Using 
molecular simulation structures, it was shown that there are slight structural 
differences in the cytoplasmic domain between the phosphorylated and 
unphosphorylated forms of Vpu, with the phosphorylated protein adopting a more 
compact structure in comparison to the unphosphorylated protein (Lemaitre et al., 
2006), as depicted in Figure 1.1 A and B. This may be because in the absence of 
phosphorylation, the C-terminal helix of the cytoplasmic domain would seem to lie 
in the aqueous phase and the phosphorylation of the conserved serine residues 
in the linker region is thought to have an effect on the secondary structure, 
resulting in the shift of the C-terminal helix to a position that is parallel to the first 
cytoplasmic helix (Lemaitre et al., 2006). Nuclear overhauser effect (NOE) 
spectra have suggested that the two cytoplasmic helices lie in an antiparallel 
formation and that there is likely to be spatial proximity between the C-terminal 
region and the linker region containing the phosphorylated serines. The side 
chains of the serine residues are thought to be exposed to the buffer or solvent, 
making these residues accessible to casein kinase II for phosphorylation (Wittlich 
et al., 2009). Vpu is mostly found to be in the ER and Golgi apparatus but may 
also be found to some extent at the plasma membrane (Pacyniak et al., 2005; 
Hussain et al., 2007); however Vpu is not found in culture fluid or supernatant, 
suggesting that the protein is not associated with virions (Ma et al., 2002). Vpu is 
able to form oligomeric complexes with itself through the action of the 
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transmembrane domain even in the absence of a membrane environment and it 
has been shown in silico as well as in vitro to form pentamers (Maldarelli et al., 
1993; Kukol and Arkin, 1999; Hussain et al., 2007).  
 
1.2.3 The primary functions of Vpu 
The two primary functions of Vpu are the release of new virus particles from 
infected cells and the degradation of CD4, the primary receptor protein for HIV-1. 
The second function occurs through the binding of beta-transducin repeat-
containing protein (β-TrCP), which requires the cytoplasmic domain of Vpu with 
the two phosphorylated serine residues. These two functions occur within 
separate cellular compartments; therefore Vpu operates at different locations 
within the cell (Schubert and Strebel, 1994). These functions have been shown to 
rely on the two distinct domains of Vpu. A Vpu mutant that only contains the 
transmembrane domain was unable to target CD4 for degradation but was 
partially able to enhance virus release in comparison to wild-type Vpu (Schubert 
et al., 1996). To add to this, a Vpu mutant with a randomized transmembrane 
domain was able to induce CD4 degradation, while the release of virus in the 
presence of this mutant were completely abrogated and levels of virus released 
were comparable to those in the absence of Vpu. This indicates that an intact 
cytoplasmic domain is required for CD4 degradation with the transmembrane 
domain only functioning as a membrane anchor for this particular function, while 
an intact transmembrane domain is needed for the efficient release of newly 
assembled virus particles from the membrane (Schubert et al., 1996). However, it 
has been shown that mutations within different regions of the transmembrane 
domain may play different roles in terms of CD4 degradation (Tiganos et al., 
1998). In this regard, it was found that mutations within the N-terminal or middle 
portions of the transmembrane domain have no effect on the ability of Vpu to 
bind to and degrade CD4, while a mutation within the C-terminal portion of the 
transmembrane domain resulted in the total loss of binding between Vpu and 
CD4. This particular transmembrane mutant had the conserved tryptophan 
residue (Trp22) moved to a position that is two residues C-terminal to its original 
position, which may affect the overall conformation of the protein within this 
domain and thus possibly influence the ability of Vpu to bind to CD4. 
Simultaneously, these mutants had a reduced efficiency with regard to virus 
particle release (Tiganos et al., 1998), which rather suggests that the overall 
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structure of the whole Vpu protein contributes to both of these functions. The two 
main functions of Vpu contribute together to an increase in the production of new 
viruses (Ma et al., 2002) and without an active Vpu protein, new virions collect 
within the cell and lead to cytotoxicity (Marassi et al., 1999). 
 
Initially it was thought that Vpu is able to promote the release of new viruses 
through the formation of Vpu oligomeric complexes in the transmembrane 
domain, as these have an ion channel activity within cell membranes (Willey et 
al., 1992a; Chen et al. 1993; Strebel, 1996; Schubert et al., 1998; Hussain et al., 
2007). However, more recent studies have shown that Vpu functions to promote 
virus release through the mechanism of antagonising the host restriction factor, 
tetherin, otherwise known as bone marrow stromal cell antigen (BST-2) (Neil et 
al., 2008; Van Damme et al., 2008; Skasko et al., 2011). This leaves the purpose 
of the ion channel activity of Vpu unclear, as mutational studies indicated that 
Vpu defective in the ability to form ion channels was still able to co-localize with 
and effectively inhibit tetherin (Skasko et al., 2011). However it has been 
suggested that the ion channel activity influences the levels of intracellular 
calcium (Willey et al., 1992a; Willey et al., 1992b) and that this leads to a 
decrease of calcium within the lumen of the ER. This ultimately expedites the 
degradation of proteins retained within the ER, as depleted levels of calcium in 
the ER stimulate an increase in the rate of proteolysis within this compartment 
(Wileman et al., 1991). 
 
1.2.4 Additional functions of Vpu 
There are other important functions of Vpu including the induction of apoptosis in 
infected cells, the modulation of major histocompatibility complex class I (MHCI), 
the counteraction of the host restriction factor tetherin which functions to inhibit 
the release of new virus particles from the cell, the regulation of gp160 
processing into gp120 and gp41 for virus assembly, as well as the finding that 
Vpu affects the down regulation of the major histocompatibility complex class II 
(MHCII) by binding the invariant chain (CD74) via interactions between their 
cytoplasmic domains (Willey et al., 1992b; Kerkau, 1995; Strebel, 1996; Marassi 
et al., 1999; Hussain et al., 2008; Nomaguchi et al., 2008). 
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1.2.4.1 Vpu in apoptosis 
Vpu has been shown to induce apoptosis in HIV-1-infected T cells (Akari et al., 
2001). Nuclear factor κB (NF-κB) is found in an inactive form bound to its 
inhibitor, IκB, within the cytoplasm. Upon degradation of IκB and the stimulation 
of cells with cytokines or chemokines, NF-κB becomes activated and moves to 
the nucleus where it activates gene expression of factors, for example B cell 
activating factor (BAFF) and chemokine (C-C motif) ligand 5 (CCL5), that are 
implicated in the activation and development of B and T cells (Bour et al., 2001). 
Vpu that contains the two phosphorylated serine residues is able to bind to β-
TrCP thereby inhibiting the degradation of IκB, which finally prevents the 
activation of NF-κB. The decrease in active NF-κB ultimately leads to a decrease 
in the expression of antiapoptotic proteins, such as Bcl-2 (section 1.5). In 
conjunction with increased caspase-3 levels, this caused apoptosis within HIV-1 
infected T cells (Akari et al., 2001) although it has been suggested that this 
finding may differ depending on which HIV-1 isolate is investigated as well as the 
type of cell that is infected (Komoto et al., 2003). This was demonstrated through 
the use of primary CD4+ T cells and human MT-4 cells as these cells responded 
differently to apoptosis induction by HIV-1 isolates with different Vpu mutations 
(Komoto et al., 2003). It is likely that the phosphorylation of serine residues are 
important for a protein to be recognized and bound by β-TrCP as other targets for 
β-TrCP degradation have also been found to contain phosphorylated serine 
residues. Although there are both phosphorylated and unphosphorylated forms of 
Vpu within a cell, HIV-1 Vpu is for the most part found to be phosphorylated, 
indicating that Vpu and β-TrCP may form highly stable complexes. As Vpu 
accumulates within the cell over time, this prolonged interaction between Vpu and 
β-TrCP results in a continued inhibition of other β-TrCP functions. It was 
previously thought that Vpu itself is not degraded as a consequence of its 
interaction with β-TrCP (Bour et al., 2001). However, Belaϊdouni et al. (2007) 
have shown ubiquitination and 26S proteasomal degradation of wild-type Vpu 
within HeLa cells, but not of a Vpu phosphorylation mutant with substitutions at 
residues 52 and 56, indicating that Vpu is degraded through interaction with β-
TrCP and the conserved phosphorylated serine residues are required for this. 
Further to this, Vpu has another serine residue at position 61 which facilitated the 
degradation of Vpu when this residue is phosphorylated (Estrabaud et al., 2007). 
Therefore the differential phosphorylation of Vpu determines which protein will be 
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ubiquitinated and degraded – either the target host protein or Vpu itself. The 
mutation of this serine residue (position 61) with an alanine has been shown to 
stabilize the protein (Hill et al., 2010).  
 
1.2.4.2 Downregulation of MHCI 
Another function of Vpu is the modulation of MHCI molecules. Although Nef is 
considered to be the major viral protein involved in MHCI downregulation (Specht 
et al., 2010), Vpu is also involved in this function, though through a different 
mechanism. This reportedly occurs through the interference of the biosynthetic 
pathway of MHCI molecules by Vpu within the ER. It is possible that this is 
achieved by the ability of Vpu to induce the degradation of MHCI molecules 
before they can reach the cell surface, similar to that of CD4 (Kerkau et al., 
1997). However, the specific degradation of MHCI molecules through interaction 
with Vpu has not yet been expressly indicated.  
 
1.2.4.3 Inhibition of Tetherin 
Yet another protein that is inhibited or antagonized by Vpu is the host restriction 
factor tetherin. Tetherin is a membrane protein that is induced by interferon-α 
(IFN-α) and is expressed on the cell surface of differentiated B cells and bone 
marrow stromal cells (Neil et al., 2008). Tetherin is a 30-36 kDa type II 
transmembrane protein that consists of an N-terminal cytoplasmic domain, a 
transmembrane domain, a coiled-coil extracellular domain as well as a C-terminal 
glycosyl phosphatidylinositol (GPI) membrane anchor (Skasko et al., 2011). It is 
believed that the GPI anchor is essential for the inhibition of viral release from the 
cell as removal of this domain completely suppresses the function of tetherin 
(Neil et al., 2008). It has been shown that tetherin functions to harness newly 
assembled virions to each other as well as to the cell membrane. Vpu has been 
found to co-localize with tetherin and these two proteins interact specifically 
through the binding of their transmembrane domains. Not all cell types require 
Vpu for virion release. However, those cell types that are dependent on Vpu for 
this function, but that are deficient in Vpu, show the accumulation of mature and 
assembled virions at the surface which later are internalized to the endosomes 
(Neil et al., 2008). The ability of Vpu to inhibit tetherin at the surface of the cell 
relies on both the transmembrane domain of Vpu as well as the conserved serine 
residues in the cytoplasmic linker region. This would suggest that Vpu targets 
tetherin for proteasomal degradation. However it was found that inhibition of the 
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proteasome had little effect on the ability of Vpu to antagonize tetherin (Van 
Damme et al., 2008). Previous studies reported the possibility that Vpu 
downregulates tetherin by trapping it within the Golgi network (Dubé et al., 
2010b) and an ER-associated protein degradation (ERAD) type of degradation 
(Mangeat et al., 2009). More recently it was shown that Vpu rather targeted cell 
surface tetherin and removed it directly from the plasma membrane (Skasko et 
al., 2011) thus greatly enhancing virion release. 
 
1.2.4.4 Regulation of Env/CD4 complexes 
Vpu regulates the formation of Env/CD4 complexes within the ER in HeLa cells 
(Willey et al., 1992b). This allows for the processing of Env to form gp120 and 
gp41 as Vpu appears to disrupt the Env/CD4 complexes by targeting CD4 for 
proteasomal degradation. Gp120 and gp41 are required for the assembly of new 
viruses; therefore Vpu indirectly plays a role in particle assembly. This function is 
described in more detail in section 1.3.2 (Marassi et al., 1999; Nomaguchi et al., 
2008). 
 
1.2.4.5 Vpu protects infected cells from lysis 
Natural killer (NK) cells play a vital role in the immune system as they are able to 
lyse specific targeted cells and are thus important as a line of defence against 
viral infections. These cells need to be regulated either by activation or 
inactivation by a variety of receptors in order to carry out their immune functions. 
The NK-T and B cell antigen (NTB-A) is one such receptor that functions as a 
coactivator to instigate the degranulation of NK cells in which lytic granules are 
produced and released in order to facilitate lysis of the target cell (Richard and 
Cohen, 2010). Vpu binds to NTB-A, an interaction that is reliant on the Vpu 
transmembrane domain, and in so doing mediates the downregulation of NTB-A 
on the cell surface which restricts the degranulation of NK cells. This in turn 
protects the infected cells from lysis (Shah et al., 2010). 
 
Similar to the downregulation of NTB-A, Vpu also downregulates CD1d at the cell 
surface. This protein is expressed on antigen presenting cells (APCs) including 
monocytes, dendritic cells as well as macrophages, and is involved in the 
presentation of lipid antigens to natural killer T (NKT) cells. Vpu binds to CD1d 
thereby causing a downregulation of this protein on APCs (reviewed in Dubé et 
al., 2010). Vpu co-localizes with CD1d within intracellular compartments, 
10 
 
indicating that there is an interaction between these two proteins which allows 
Vpu to interfere with the recycling of CD1d from intracellular compartments to the 
cell surface. A reduction in the surface expression of CD1d leads to a decrease in 
the activation of NKT cells; therefore this is yet another way in which Vpu 
functions to protect infected cells from lysis and ultimately impair the 
development of immune responses. It is interesting to note that CD1d, like many 
other host factors, is targeted by both Vpu as well as Nef (Moll et al., 2010). 
 
1.2.4.6 Vpu inhibits NF-κB pathways 
Another way in which Vpu may undermine the immune system is by possibly 
preventing the translocation of the CD74 intracellular cytoplasmic domain 
fragment (CD74-ICD) to the nucleus. This would prevent the initiation of the NF-
κB signal cascade that affects B cell maturation, proliferation and survival, as 
explained in detail in section 1.5. There may be many additional consequences to 
the effect of Vpu on the NF-kB pathways, however there are multiple other HIV-1 
proteins that are involved in the decrease of antiapoptotic proteins or the 
induction of apoptosis, such as Nef, Tat, Vpr and Env (Komoto et al., 2003; 
Nomaguchi et al., 2008). For example, Nef also affects antigen presentation by 
MHCII molecules as it upregulates the expression of CD74 at the cell surface 
(reviewed in Kirchhoff, 2010), thereby preventing it from complexing with 
immature MHCII in the ER, as well as contributing to the modulation of NF-κB 
pathways by preventing the release of CD74-ICD from the plasma membrane. 
This indicates that Vpu does not positively influence viral persistence alone, but 
rather contributes to this along with other HIV-1 proteins. Nef and Vpu in 
particular seem to work in conjunction for a greater overall effect on the immune 
system. 
 
In summary, Vpu has many crucial functions by which it contributes to the 
impairment of the immune system and disease outcome. It plays an important 
role in multiple key aspects of the immune system, including antigen 
presentation, induction of apoptosis, prevention of the lysis of infected cells and 
interference with the expression of survival proteins within immune cells to name 
a few.  
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1.3 CD4 degradation through binding Vpu 
1.3.1 Introduction to CD4 
As previously mentioned in sections 1.2.3 and 1.2.4, Vpu has a variety of 
approaches by which it undermines the immune system. One of the most 
documented approaches would be the targeting of CD4 for degradation (Willey et 
al., 1992a; Chen et al., 1993; Schubert et al., 1998). As CD4 is an important 
protein in the immune response, Vpu significantly debilitates the immune system 
by targeting this protein for degradation. CD4 is a 55 kDa class I membrane 
glycoprotein that consists of a lumenal domain, a transmembrane domain and a 
38 residue cytoplasmic domain (Willey et al., 1992a). NMR structural analyses 
indicate that the transmembrane α-helix spans residues 372-395 and the 
amphipathic cytoplasmic α-helix comprises of residues 403-413 and is positioned 
closely to the membrane, while the C-terminus remains unstructured (Wittlich et 
al., 2010). This protein is synthesized within the ER and is transported to the cell 
surface through the Golgi network (Willey et al., 1992a) and is expressed on a set 
of T lymphocytes which are able to recognize antigen presenting MHCII 
molecules (Schubert et al., 1998; Wittlich et al., 2010). 
 
CD4 is a highly important component for the proper functioning of the immune 
system as it assists with the protection against both intracellular and extracellular 
parasites, bacteria and viruses. It is involved in many different roles including the 
production of cytokines, recruitment of neutrophils, basophils and eosinophils, as 
well as assisting B cells with the production of antibodies (Killar et al., 1987; 
Mosman and Coffman, 1989; Paul and Seder, 1994; Weaver et al., 2006; 
reviewed in Zhu and Paul, 2008) and it also serves as the primary receptor for 
HIV-1 in order for HIV-1 to gain entry to the cell (Schubert et al., 1998). 
Additionally, downregulation and degradation of CD4 modulates the activation of 
T lymphocytes and also prevents the superinfection of the host (Magadan et al., 
2010). 
  
1.3.2 Multiple HIV-1 proteins target CD4 
CD4 is targeted by three separate viral proteins, namely Nef, Env and Vpu. Nef 
binds to the cytoplasmic domain of CD4 thereby reducing the surface expression 
of CD4 in particular by targeting CD4 for internalization or endocytosis via a 
clathrin-dependent process, leading to subsequent lysosomal degradation. The 
Env precursor, gp160, binds to CD4 within the ER and acts as a trap by 
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preventing newly synthesized CD4 from moving to the cell surface (Nomaguchi et 
al., 2008; Wittlich et al., 2010; reviewed in Andrew and Strebel, 2010). CD4 has 
been shown to be degraded in the ER after co-expression with Vpu in HeLa cells 
(Willey et al., 1992a; Bour et al., 1995), which not only affects the recognition of 
MHCII presenting molecules, but also frees the Env precursor thereby allowing 
for both the maturation and trafficking of Env (Nomaguchi et al., 2008). The 
formation of Env/CD4 complexes is of some importance in Vpu-mediated 
degradation of CD4, although Env itself is not able to induce CD4 degradation. 
This is because even in the absence of Env, Vpu is still able to degrade CD4 as 
long as CD4 is unable to move out of the ER, further indicating that Env functions 
only as a trap (Willey et al., 1992a). This is further supported by data indicating 
that not only Env, but interactions between the transmembrane domains of Vpu 
and CD4, as well as the polyubiquitination of the CD4 cytoplasmic region, also 
serve to trap CD4 within the ER (Magadan et al., 2010). Similarly, in the absence 
of CD4, Vpu is not involved in the processing of Env (Willey et al., 1992b). 
However, if CD4 remains bound to Env in the ER, the processing of Env is 
inhibited resulting in downstream consequences for new virus formation (Marassi 
et al., 1999). Using fluorescence activated cell sorting (FACS)-based Fӧrsters 
resonance energy transfer (FRET), it was shown that Nef and Vpu were found in 
their expected locations within the cell, i.e. Nef at the plasma membrane and Vpu 
at the ER, Golgi and plasma membrane (Banning et al., 2010). The binding of 
Nef and Vpu to CD4 within their respective cellular compartments was also 
corroborated using this approach (Banning et al., 2010). These two viral proteins 
work together to target CD4 as Vpu cannot bind to CD4 at the cell surface and 
Nef cannot prevent the movement of CD4 from the ER to the cell surface 
(reviewed in Andrew and Strebel, 2010). The combined effect of both Nef and 
Vpu on the downregulation of CD4 leads to a continuous downregulation of this 
protein, as Nef is expressed early in infection and targets pre-existing CD4, while 
Vpu is expressed at a later stage and targets newly synthesized CD4 (Magadan 
et al., 2010). Therefore, the downregulation of CD4 appears to be of significance 
to HIV-1 as it dedicates two accessory proteins to this function. 
 
1.3.3 CD4 degradation 
There have been conflicting reports regarding the involvement of the ERAD 
pathway in Vpu-mediated CD4 degradation. This arises from the fact that there 
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are multiple ERAD pathways with varying mechanisms of targeting proteins that 
have imperfections in one or more of their domains. However it has been found 
that the Vpu-mediated degradation of CD4 relies on the VCP-UFD1L-NPL4 
complex to disassociate CD4 from the ER membrane. This complex is a vital 
element of the ERAD mechanism, thus indicating that the degradation of CD4 is 
in part reliant on this pathway (Magadan et al., 2010). To add to this, it was found 
that Vpu-mediated degradation of CD4 is unable to occur in the absence of the 
AAA ATPase Cdc48/p97, which is required to extract ERAD proteins from the ER 
membrane in order for these proteins to be degraded by the 26S proteasome 
(Binette et al., 2007). The ability of Vpu to induce degradation of CD4 was 
blocked by the use of proteasome inhibitors and required cytosolic protein 
polyubiquitination machinery that targets ubiquitination sites in the CD4 
cytoplasmic domain (Fujita et al., 1997; Schubert et al., 1998). The use of 
proteasome inhibitors did not hinder the binding between Vpu and CD4. It was 
also found that the ubiquitin-activating enzyme E1, which is required to attach 
ubiquitin to proteins, is involved in Vpu-mediated CD4 degradation (Schubert et 
al., 1998). It should be noted that protease inhibitors which do not affect the 
proteasome were not able to prevent the Vpu-mediated degradation of CD4 
(Fujita et al., 1997). Also, the degradation of CD4 by Vpu is not affected by the 
inhibition of the lysosomal protein degradation machinery. This degradation 
process is membrane-dependent and requires the expression of both CD4 and 
Vpu within the same membrane compartment. Additionally, Vpu is able to target 
both glycosylated and unglycosylated forms of CD4 (Chen et al., 1993; Schubert 
et al., 1998). 
 
1.3.4 Vpu/CD4 specific interactions for degradation 
The cytoplasmic tail of CD4 is necessary for sensitivity to Vpu as this region 
contains the binding site for Vpu as well as sequences that are significant for 
degradation (Willey et al., 1994; Bour et al., 1995). Removal of 13 residues from 
the cytoplasmic tail of CD4 did not affect the ability of Vpu to cause the 
degradation of CD4, yet the removal of 32 residues from the CD4 cytoplasmic tail 
was reported to prevent Vpu-mediated degradation of CD4 (Chen et al., 1993). 
This indicates that a region of approximately 19 residues (from 402 to 420) within 
the CD4 cytoplasmic domain is needed for Vpu-mediated degradation (Chen et 
al., 1993). This Vpu-responsive region lies close to the membrane and contains 
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two phosphorylated serine residues, which are not involved in Vpu-mediated 
degradation (Willey et al., 1994). This same region on CD4 was found to be 
important in the binding of Vpu, and not only important for degradation. CD4 
mutants that lacked this binding site were not sensitive to Vpu-mediated 
degradation providing evidence that the binding interaction between CD4 and 
Vpu is necessary for degradation (Bour et al., 1995). In addition to this, a mutant 
CD4KRcyto having lysine substituted with arginine at positions 411, 417, 418 and 
428 within the cytoplasmic domain of CD4, was found to be stable in the 
presence of Vpu. Despite this, the CD4KRcyto mutant was still able to bind to Vpu, 
thus suggesting that the ubiquitination of the lysine residues may be required for 
Vpu-mediated CD4 degradation (Schubert et al., 1998). More specifically, Bour et 
al. (1995) described two discrete amino acid sequences in the cytoplasmic tail of 
CD4, namely EKKTCQCP and LSEKKT, the removal of which resulted in a 
decrease in the ability of Vpu to induce CD4 degradation. More recent studies 
have indicated that it is not only the lysine residues in the cytoplasmic domain of 
CD4 that are ubiquitinated. The same CD4KRcyto mutant was found to be 
ubiquitinated and degraded in the presence of Vpu within human embryonic 
kidney (HEK) 293T cells, although significantly less than the wild-type protein. 
This indicates that the lysine residues do play an important role in the 
ubiquitination of CD4, but they are not solely responsible for this process (Binette 
et al., 2007). Furthermore, it was demonstrated that the removal of serine and 
threonine residues in addition to lysine residues completely abolished the 
ubiquitination and degradation of CD4 in the presence of Vpu. This indicates that 
there are multiple ubiquitin target sites within the CD4 cytoplasmic domain 
(Magadan et al., 2010). It is not only specific amino acid sequences that are 
required for binding of CD4 to Vpu. It has been shown that the presence of a 
membrane proximal α-helix within the CD4 cytoplasmic domain is needed in 
order to bind to Vpu as it may provide an interface for this protein interaction, and 
the disruption of this α-helix abrogates the degradation of CD4 through 
interaction with Vpu. However, CD4 mutants that have an altered primary 
sequence, but that are still able to form an α-helix, are also still capable of 
binding Vpu (Tiganos et al., 1997), indicating that structural determinants may be 
of a greater significance for binding than sequence alone. 
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Sequences in the cytoplasmic domain of Vpu are also needed to induce the 
degradation of CD4 (Chen et al., 1993; Bour et al., 2001). The CD4 binding site 
on Vpu overlaps with the immunodominant domain, as CD4 prevents the binding 
of antibodies directed against the Vpu cytoplasmic domain (Schneider et al., 
1990; Bour et al., 1995). In a similar study, it was also shown that an antibody 
directed against a Vpu cytoplasmic peptide with the sequence HAPWDVDDL was 
masked through the binding of CD4 to Vpu (Tiganos et al., 1997), suggesting that 
this sequence is part of the binding region for CD4. It has been shown that the 
cytoplasmic region of Vpu contains an invariant sequence of 10 residues and that 
a deletion of only a portion of this sequence or a deletion of only 6 C-terminal 
residues severely limits Vpu-mediated CD4 degradation (Chen et al., 1993). As 
such, it has been suggested that this region is an active site on Vpu as it is found 
on the same side of the membrane and possibly lines up with the Vpu-responsive 
region on CD4 which indicates the possibility that these are the interacting 
regions on the two proteins (Willey et al., 1994). Additional studies have also 
shown that the membrane proximal α-helix in the Vpu cytoplasmic domain is 
required for CD4 binding. Specifically, mutational studies indicated that residues 
28-47 and 76-81 in the cytoplasmic domain of Vpu are needed in order to bind 
CD4 (Margottin et al., 1996). Further to this, it has been shown that the overall 
secondary structure of the Vpu cytoplasmic domain is necessary in order to 
mediate the degradation of CD4, as mutants containing disruption in either of the 
Vpu cytoplasmic α-helices were unable to target CD4 for degradation, even 
though these mutations did not affect the phosphorylated serine residues in the 
linker region (Tiganos et al., 1997). Alanine-scanning mutagenesis was used to 
identify specific residues within the second cytoplasmic helix of Vpu that may be 
involved in CD4 downregulation. This approach allowed for the identification of a 
highly conserved leucine at position 63 that is essential for CD4 downregulation, 
as well as valine at position 68 that is also important for this particular function of 
Vpu (Hill et al., 2010). Chemical shift perturbation (CSP) analysis likewise 
showed that both cytoplasmic α-helices of Vpu are involved in binding CD4, 
though the C-terminal α-helix demonstrated the most substantial chemical shift 
changes which suggests that this helix has a more pronounced role in binding 
CD4 compared to the membrane-proximal helix (Singh et al., 2012). As previous 
studies indicated that while both α-helices are necessary for degradation and 
only the first α-helix is needed for binding (Tiganos et al.1997), it is possible that 
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the binding of CD4 induces a conformational change in Vpu that is more suitable 
for the downstream events leading to CD4 degradation. 
 
Although binding of Vpu to CD4 is necessary for CD4 degradation, this step 
alone is not enough to induce degradation. Two Vpu mutants, a deletion mutant 
and a phosphorylation mutant, were both able to bind to CD4 but were unable to 
induce degradation (Bour et al., 1995), indicating that phosphorylation is not 
required for Vpu binding to CD4. However, this does indicate that 
phosphorylation of the serine residues in Vpu (Ser52 and Ser56) is required for 
CD4 degradation (Bour et al., 1995). Vpu acts as a molecular adaptor by 
recruiting the E3 ubiquitin ligase complex to CD4 in the ER for degradation by 
proteasomes (Nomaguchi et al., 2008; reviewed in Andrew and Strebel, 2010). 
Vpu has been found to interact with human β-TrCP and the phosphorylation of 
two serine residues in the Vpu cytoplasmic domain at positions 52 and 56 is 
necessary for this binding. The most well-known consensus sequence for β-TrCP 
binding is DSPGΦXSP where SP is a phosphorylated serine, Φ is a hydrophobic 
residue and X is any other residue (Nomaguchi et al., 2008). It must be noted that 
there are other sequences that β-TrCP recognizes for binding (Belaϊdouni et al., 
2007). β-TrCP contains seven WD repeats that are involved in mediating the 
interaction with Vpu in a phosphoserine-dependent manner. It also contains an F-
box domain that targets the substrate protein for degradation by allowing the 
interaction of β-TrCP with Skp1p, a factor that provides a link to the ubiquitin 
proteolysis machinery. This shows that the binding sites on Vpu for CD4 and β-
TrCP are separate and independent of each other (Margottin et al., 1998; 
reviewed in Andrew and Strebel, 2010). In this way, CD4 becomes 
polyubiquitinated along its cytoplasmic domain and is therefore targeted for 
proteasomal degradation through the binding of Vpu (Hussain et al., 2008). 
  
It has been proposed by Margottin and co-workers (1998), that the degradation of 
CD4 may be summarized as follows: infection of cells with HIV-1 leads to the 
formation of CD4-Env complexes in the ER, trapping CD4. The cytoplasmic 
domain of Vpu binds to the cytoplasmic domain of CD4 and β-TrCP is then 
recruited to the Vpu/CD4 complex. The ternary complex consisting of Vpu/CD4/β-
TrCP then recruits Skp1p and ultimately the E3 ligase complex, leading to the 
ubiquitination and degradation of CD4. CD4 is unable to bind to β-TrCP in the 
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absence of Vpu, indicating that Vpu is a linker protein between CD4 and β-TrCP 
(Margottin et al, 1998). This is represented schematically in Figure 1.2. Vpu itself 
is not degraded in the process (Nomaguchi et al., 2008). As previously 
highlighted in section 1.3.2, retention of CD4 in the ER is a requirement for 
degradation, as Vpu is unable to degrade any CD4 molecule that has already 
exited the ER. The degradation of CD4 within the ER ultimately results in 
decreased cell surface levels of CD4, thereby impairing the immune system 
(Strebel, 1996). However, even though the degradation of CD4 is sufficient for 
effective immune impairment (Wonderlich et al., 2011), Vpu has many other 
functions, including the targeting of antigen presentation through downmodulation 
of the MHCII. 
  
 
Figure 1.2: Schematic representation of CD4 degradation through binding human 
immunodeficiency virus type-1 (HIV-1) viral protein “u” (Vpu). Vpu binds CD4 in the 
endoplasmic reticulum (ER) and targets CD4 for proteasomal degradation through the 
recruitment of the E3 ligase complex. CD4 becomes ubiquitinated and is degraded by the 
action of the 26S proteasome. This not only impairs the immune system to a large extent, 
but it also results in the release of the HIV-1 envelope (Env) protein for further processing 
and new virion assembly (adapted from Nomaguchi et al., 2008; reviewed in Andrew and 
Strebel, 2010). 
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1.4 Major Histocompatibility Complex Class II 
The ability of the immune system to respond to infections is reliant on the 
presentation of foreign antigens or peptides to the T cells by the MHC molecules 
(reviewed in Peters and Sperber, 1999). While MHCI molecules display peptides 
derived from intracellular microorganisms within the cytoplasm, particularly 
viruses, to the CD8+ cytotoxic T cells, MHCII molecules present foreign peptides 
or antigens derived from extracellular microorganisms within the endosomal-
lysosomal system including viruses, bacteria, protozoan parasites and cell 
surface proteins to CD4+ helper T lymphocytes. The CD8+ T cells are known to 
directly lyse infected cells and the CD4+ T helper cells activate B lymphocytes as 
well as macrophages, leading to the production of antibodies and the destruction 
of bacteria, respectively. CD8 and CD4 co-receptors on cytotoxic and –helper T 
cells, respectively, function to recognize the non-polymorphic regions of MHCI 
and MHCII, respectively (Ploegh, 1998; Robertson, 1998). The recognition of viral 
antigens by CD4+ T helper cells that are presented by the MHCII also results in 
the production of cytokines, which in turn galvanizes the differentiation of CD8+ 
cytotoxic T lymphocytes (CTLs) that inhibit the replication of the virus through cell 
lysis, and leads to the spread and differentiation of macrophages and B 
lymphocytes (Miller and Sedmak, 1999; reviewed in Peters and Sperber, 1999). 
MHCII molecules are typically only expressed within a specific set of cells that 
are involved within the immune system such as APCs, B cells, macrophages, 
dendritic cells, Langerhans cells as well as endothelial cells (Robertson, 1998; 
reviewed in Peters and Sperber, 1999). Along with CD74, MHCII can also be 
expressed in response to cytokines (Boss, 1997; Miller and Sedmak, 1999). 
 
The downregulation of MHCI is facilitated mostly by the HIV-1 Nef protein in order 
to prevent the lysis of infected T cells by CTLs (Specht et al., 2010). Nef functions 
to remove MHCI molecules directly from the cell surface by the ADP ribosylation 
factor 6 (ARF6) endocytic pathway using the phosphofurin acidic cluster sorting 
protein-1 (PACS-1). This endocytosis moves the MHCI to the trans-Golgi network 
(Blagoveshchenskaya et al., 2002). As previously mentioned in section 1.2.4.2, 
MHCI molecules are also targeted by HIV-1 Vpu. However, this downregulation 
occurs rather by the interaction of Vpu with immature MHCI molecules within the 
ER, instead of at the cell surface (Kerkau et al., 1997). Similarly, mature MHCII 
molecules are downregulated by both Nef and Vpu. Nef upregulates the cell 
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surface expression of CD74, and is also capable of upregulating immature MHCII 
molecules at the cell surface, while at the same time decreasing the levels of 
mature, peptide-loaded MHCII at the cell surface. This interferes with antigen 
presentation (Stumptner-Cuvelette et al., 2001; reviewed in Kirchhoff, 2010; 
Ghiglione et al., 2012). Once again, Vpu acts from within the ER, where it binds 
to CD74 and also prevents formation of the mature MHCII complex (Hussain et 
al., 2008). In this way, these two accessory proteins of HIV-1 work together to 
target both antigen presenting complexes to prevent infected cells from being 
recognized by CD8+ T lymphocytes or CD4+ T helper cells. 
 
MHCI and MHCII differ slightly in terms of structure (Figure 1.3 and Figure 1.4, 
respectively). Similarities between the two classes include a peptide binding cleft 
and both are expressed from multiple genes which allows both molecule types to 
have considerable polymorphism in order to bind and display a large variety of 
peptides (Robertson, 1998). MHCII has a larger peptide binding cleft in 
comparison to MHCI, which allows these molecules to bind a more 
comprehensive assortment of antigens than MHCI (reviewed in Peters and 
Sperber, 1999). 
 
 
Figure 1.3: Schematic representation of the structure of a major histocompatibility 
complex class I (MHCI) molecule. These molecules have a cytoplasmic domain, 
transmembrane domain as well as an extracellular domain that either projects into the 
lumen of the endoplasmic reticulum (ER) or is displayed on the surface of the cell. MHCI 
molecules are made up of three α chains that are linked to a β2 microglobulin chain and 
have a relatively small peptide-binding cleft (adapted from Peters and Sperber, 1999). 
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Figure 1.4: Schematic representation of the structure of a major histocompatibility 
complex class II (MHCII) molecule. As with MHCI molecules, these molecules also 
have a cytoplasmic domain, transmembrane domain as well as an extracellular domain 
that either projects into the lumen of the endoplasmic reticulum (ER) or is displayed on 
the surface of the cell. MHCII molecules are made up of two α chains and two β chains 
and have a larger peptide-binding cleft in comparison to MHCI (adapted from Peters and 
Sperber, 1999).  
 
The MHCII molecules are transmembrane glycoproteins (Warmerdam et al., 
1996) and are made up of three α and β glycoprotein noncovalently-associated 
dimers that consist of a cytoplasmic domain, transmembrane domain and 
extracellular domain. The newly synthesised immature complex of three αβ 
dimers then associates with a homotrimer of CD74, or invariant chain, within the 
lumen of the ER. At this stage, the complex is unable to bind any peptides as 
CD74 is bound to the class II molecules in such a way that it acts to prevent the 
binding of peptides within the ER compartment (reviewed in Cresswell, 1996). 
The trafficking of MHCII complexes from the ER to endocytic compartments is 
determined by two dileucine-based target motifs in the cytoplasmic domain of 
CD74 (Kang et al., 1998; Miller and Sedmak, 1999; Szaszak et al., 2008). Once 
within the endocytic compartment, CD74 is proteolytically broken down by 
cathepsins which leave behind the class-II-associated Ii-chain peptide (CLIP) 
fragment within the peptide binding cleft. The CLIP fragment of CD74 seems to 
bind to class II molecules in a manner highly similar to that of a foreign peptide 
through a labyrinth of hydrogen bonds. It has been proposed that the three class 
II αβ dimers mainly associate with CD74 by the interaction between the CLIP 
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fragment of CD74 and the peptide binding cleft of the class II molecules. This 
interaction may also be stabilized by a small degree of association at the C-
terminal region of CD74 (reviewed in Cresswell, 1996). The exchange of CLIP 
with a foreign peptide is facilitated by the human leukocyte antigen-DM (HLA-DM) 
within a lysosome-like compartment before the mature complex can move to the 
cell membrane to present the foreign peptide to the CD4+ T helper cells (Ploegh, 
1998; Miller and Sedmak, 1999; reviewed in Peters and Sperber, 1999). It has 
been found that there is a collection of endocytic compartments for peptide 
loading of MHCII molecules, and this includes early endosomes, late endosomes 
or pre-lysosomes as well as multivesicular bodies (Warmerdam et al., 2006). 
 
However, antigen presentation may only be one reason why HIV-1 causes the 
downregulation of MHCII molecules in infected cells. It has been found that the 
assembly and budding of HIV-1 may occur either at the plasma membrane or in 
late endosomes/multivesicular bodies, depending on the cell type. For example, 
in T lymphocytes and some human cell lines HIV-1 assembles at the plasma 
membrane, while in macrophages, HIV-1 assembles in the late 
endosomes/multivesicular bodies (Pelchen-Matthews et al., 2003; Ono and 
Freed, 2004). Interestingly, it was shown that the cytoplasmic domains of human 
leukocyte antigen-DR (HLA-DR), which is an important component of the MHCII 
molecule, affects the assembly and budding of HIV-1 in such a way that it is 
directed away from the plasma membrane and rather to the late 
endosomes/multivesicular bodies (Finzi et al., 2006). HLA-DR specifically acts on 
the relocation of the HIV-1 Gag protein, which is needed for the assembly of virus 
particles. Although the virions in these intracellular compartments are still 
infectious, this finding suggests that the MHCII molecules may be able to reduce 
the release of new viruses from the cell surface (Finzi et al., 2006). 
  
As previously mentioned in section 1.4, HIV-1 Vpu has been found to bind to the 
cytoplasmic domain of CD74. It is interesting to note that the binding site on Vpu 
for CD74 may overlap with the immunodominant region which may also be found 
within the cytoplasmic C-terminal domain of Vpu (Schneider et al., 1990). The 
interaction between these two proteins may not necessarily only affect antigen 
presentation; it could possibly also function to prevent the redirection of HIV-1 
Gag to late endosome/multivesicular bodies to allow the virus to spread from cell 
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to cell more efficiently. However, the Vpu/CD74 interaction may have even more 
widespread downstream consequences than this, as CD74 is a ubiquitous protein 
and it is involved in many important cellular pathways, as highlighted below. 
 
1.5 CD74/Invariant chain 
CD74, the invariant chain of the MHCII, consists of a 30 amino acid N-terminal 
cytoplasmic domain, a 26 amino acid transmembrane domain and a 160 amino 
acid sequence that is either displayed on the cell surface or protrudes into the ER 
lumen, depending on the subcellular location of the protein (Claesson et al., 
1983; Strubin et al., 1984; Hussain et al., 2008). The structure of CD74 appears 
to be extended as it has a large Stokes radius of 72 Å and each of the chains that 
make up the trimer have limited interaction with each other (reviewed in 
Cresswell, 1996). A schematic representation of CD74 is given in Figure 1.5. 
 
There are multiple isoforms of CD74, designated p33, p35, p41 and p43. Ii-p33 
and Ii-p35 are 33 kDa and 35 kDa, respectively and are involved in MHCII 
antigen presentation, with the Ii-p33 isoform being the prominent of the two. 
These isoforms originate in two ways, i.e. by alternative splicing as well as 
through the use of two different translation initiation sites (Warmerdam et al., 
1996). The only difference between these isoforms of CD74 is that Ii-p35 has 16 
extra residues at the N-terminus that form part of the cytoplasmic domain. These 
additional residues differentiate between the routes by which the immature MHCII 
molecules reach the endocytic compartment for antigen loading. MHCII 
molecules that are partnered with the Ii-p33 isoform only reach the endosome via 
the cell membrane, while molecules that are partnered with the Ii-p35 isoform are 
first trafficked to the Golgi network before moving to the endosome. Finally, 
MHCII molecules that are associated with a mixture of both CD74 isoforms will be 
trafficked internally, and not via the cell membrane as the signal motif in the Ii-
p35 isoform is stronger than that of the Ii-p33 isoform (Warmerdam et al., 1996). 
The Ii-p35 isoform is phosphorylated by protein kinase C at serine residues (Ser6 
and Ser8) in the cytoplasmic region which are not found in the Ii-p33 isoform. An 
Ii-p35 phosphorylation mutant inhibits the trafficking of Ii-p35-bound MHCII via 
intracellular pathways, but does not inhibit exit of these molecules from the ER, 
indicating that the phosphorylation of this isoform is required for the trafficking of 
MHCII molecules from the Golgi network to the endosome for antigen loading 
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and finally presentation (Anderson et al., 1999). As previously mentioned in 
section 1.4, both Nef and Vpu target CD74 at the plasma membrane and within 
the ER, respectively. It is possible that the presence of the two isoforms of CD74 
that are trafficked along different pathways necessitates the function of both Nef 
and Vpu to bind to this protein. Nef would therefore target only the Ii-p33 isoform 
at the cell surface, while Vpu would interact with mainly the Ii-p35 isoform within 
the ER and Golgi network. 
 
The cytoplasmic tail of CD74 has a dileucine motif which acts as a trafficking 
signal to move CD74-associated MHCII molecules out of the ER for further 
processing. These trafficking signals are DQRDLI and EQLPML in the membrane 
distal and membrane proximal regions of the cytoplasmic domain, respectively, 
with the first motif lying within a helix and the second motif lying within a turn 
(Motta et al., 1995; Kang et al., 1998). The DQRDLI motif, in particular, is 
required for sorting the CD74-bound MHCII molecules from the Golgi network to 
the endocytic compartment, although both sorting motifs in combination have a 
greater effect than one motif alone (Kang et al., 1998). Using NMR and aqueous 
solution at physiological pH, it was determined that there is an α-helix in the 
cytoplasmic domain of CD74 from residues glutamine to leucine (Gln4 – Leu14) 
as well as a type I β turn from leucine to leucine (Leu14 – Leu17) and two type II 
β turns from arginine to alanine and from alanine to serine (Arg20 – Arg23 and 
Arg23 – Ser26) (Motta et al., 1995). However, the type I β turn can possibly be 
incorporated into the α-helix without disturbing other residues within the helix. As 
this helix would then contain proline (Pro15), the resulting helix is a kinked proline 
α-helix. The proline residue is conserved and removal of this residue prevents 
internalization of CD74 from the plasma membrane, which then suggests that this 
residue is highly relevant (Motta et al., 1995).  
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Figure 1.5: Schematic representation of CD74. The N-terminal cytoplasmic domain 
and the transmembrane domain are relatively small compared to the domain that lies 
within the lumen of the endoplasmic reticulum (ER) or that is projected extracellularly. 
The class-II-associated Ii-chain peptide (CLIP) region is indicated in blue and this is the 
section of CD74 that binds to the peptide-binding site on major histocompatibility complex 
class II (MHCII) molecules (adapted from Cresswell, 1996). 
 
The N-terminal cytoplasmic tail of the Ii-p35 isoform also contains an arginine-
based signal motif that behaves as a retention signal to keep the complex in the 
ER (Warmerdam et al., 1996; reviewed in Michelsen et al., 2005; Szaszak et al., 
2008). It is suggested that there is a general arginine consensus sequence of 
Φ/Ψ/RRXR, where Φ/Ψ is either an aromatic or a bulky hydrophobic residue and 
X is any other residue. A protein that contains more than two arginine residues, 
such as CD74, will have a notably strong retention signal (reviewed in Michelsen 
et al., 2005). However, association of CD74 with MHCII molecules is thought to 
mask this retention signal to allow the exit of the complex from the ER. 
Phosphorylation of Ser6 and Ser8 residues in close proximity to the arginine-
based retention motif by protein kinase C may also aid in the trafficking of 
molecules out of the ER. If this phosphorylation is in any way inhibited, MHCII-
associated CD74 is unable to undergo processing within the endosomes, thereby 
repressing antigen presentation (Anderson et al., 1999; Szaszak et al., 2008). 
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The expression of CD74 is separate to that of the MHCII molecules and this 
allows CD74 to have numerous other functions within the cells. CD74 is a 
regulated intramembrane proteolysis (RIP)-processed protein. RIP proteins are 
essentially transcription factors that are expressed as dormant membrane-bound 
regulatory proteins. These proteins are activated by proteolytic cleavage at the 
plane of the membrane in which they are bound which allows the released 
cytosolic fragment to migrate to the nucleus in order to modulate transcription. 
The RIP process takes place within the endocytic compartment and occurs 
through the action of intramembrane cleaving proteases (I-CLiPs). The peptide 
bond is hydrolysed in a two-step process (Becker-Herman et al., 2005). A fraction 
of CD74-ICD migrates to the nucleus where it initiates a signal cascade. This 
occurs through the activation of phosphatidylinositol 3’-kinase (PI3K), Syk 
tyrosine kinase and Akt serine/threonine kinase and this then leads to the 
activation of the NF-κB p65/RelA homodimer as well as its coactivator, TATA box 
binding protein (TBP)-associated factor II105 (TAFII105), a subunit of the general 
transcription factor IID (TFIID) (Matza et al., 2001; Starlets et al., 2006). The 
ultimate result of the signal cascade is two-fold. First, the cell enters into the 
synthesis phase (S phase) where DNA synthesis is increased, yielding an 
increase in cell division and proliferation (Starlets et al., 2006). Second, the 
expression of the TAp63 protein is upregulated by both CD74-ICD as well as the 
activated NF-κB p65/RelA homodimer. TAp63 binds to the Bcl-2 promoter and, in 
doing so, transactivates the Bcl-2 gene to increase the expression of the 
antiapoptotic protein, Bcl-2. This enhances the survival of B cells as a result of a 
decrease in apoptosis (Lantner et al., 2007). Not only is CD74 involved in the 
proliferation and survival of B cells, it also plays a role in the differentiation of B 
cells from immature to mature cells within the spleen (Matza et al., 2001; Matza 
et al., 2002a). An important point to note is that this particular signal cascade is 
eliminated by the degradation of the active CD74 protein (Lantner et al., 2007; 
Matza et al., 2002b). This particular function of CD74 is represented 
schematically in Figure 1.6. Using a similar pathway, CD74-ICD also influences 
the proinflammatory responses by altering the expression of the monocyte 
chemoattractant protein-1 (MCP-1), which is involved in the early stages of 
atherosclerosis (Martin-Ventura et al., 2009). In this case, it was found that CD74 
co-localizes with NF-κB, suggesting that these two proteins may interact within 
atherosclerotic plaques in order to increase the expression of MCP-1, which is 
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regulated by NF-κB. Overall, an increase in CD74 leads to an increase in 
inflammation during atherosclerosis (Martin-Ventura et al., 2009). Another way in 
which CD74 plays a role in inflammation is in the overexpression of CD74 on the 
surface of gastric epithelial cells due to Helicobacter pylori infection. CD74 
functions as the receptor for this bacteria and the binding of the bacteria to CD74 
not only results in the upregulation of cell surface levels of CD74, but also 
induces NF-κB pathways that result in the production of proinflammatory 
cytokines (Beswick et al., 2005; reviewed in Beswick and Reyes, 2009). CD74 
has not only been associated with inflammatory disorders, but is also implicated 
in gastrointestinal cancers, in which an overexpression of CD74 within tumour 
cells corresponds with a suppression of the immune response to the cancer 
(Ishigami et al., 2001). 
 
CD74 is also involved in the mediation of signalling on the cell surface in 
conjunction with the macrophage inhibitory factor (MIF). MIF is a cytokine that 
mediates many important pathways within the cell such as the production of other 
cytokines and nitric oxide. MIF has also been shown to bring about the 
phosphorylation and therefore, activation of the p44/p42 extracellular-signal-
regulated kinase family (ERK-1/2). The downstream consequence of this is the 
activation of effector proteins and transcription factors that are involved in 
inflammation, such as NF-κB. MIF interacts with the CD74 extracellular domain at 
the cell surface which allows MIF to bind to the cell and induce the ERK-1/2 
cascade. However, it is believed that the signal cascade generated by CD74 
requires a second messenger protein and that messenger protein may be CD44 
as studies have suggested a complex comprising MIF, CD74 and CD44 may 
exist (Meyer-Siegler et al., 2004). CD44 is a transmembrane protein that is 
involved in the activation of tyrosine kinase. Therefore, CD74 functions as a 
surface binding protein for MIF, and in conjunction with CD44, it regulates MIF’s 
functions in the cell (reviewed in Leng and Bucala, 2006). 
  
2
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Figure 1.6: Schematic representation of the signal cascade induced by the CD74 
cytoplasmic domain fragment (CD74-ICD) for cell survival. CD74 forms part of the 
major histocompatibility complex class II (MHCII) in the endoplasmic reticulum (ER). The 
complex is directed to the endosome, where intramembrane cleaving proteases (I-CLiPs) 
hydrolyze the peptide bond. The cytoplasmic fragment moves to the nucleus, where a 
signal cascade is initiated through the activation of protein kinases. This activates the 
nuclear factor-κB (NF-κB) p65/RelA homodimer and its coactivator, TBP-associated 
factor II105 (TAFII105). The cell enters the synthesis (S) phase for increased DNA 
synthesis, which causes cell division and proliferation. Simultaneously the activated NF-
κB p65/RelA homodimer upregulates TAp63 protein expression. TAp63 transactivates the 
Bcl-2 gene leading to the expression of the Bcl-2 antiapoptotic protein. This results in 
enhanced cell survival. Human immunodeficiency virus type-1 (HIV-1) infected cells 
contain viral protein “u” (Vpu) which binds to the cytoplasmic domain of CD74 in the ER. 
This not only prevents antigen presentation, but also prevents the translocation of CD74-
ICD to the nucleus. Consequently, the signal cascade affecting B cell proliferation and 
survival cannot be initiated (Le Noury et al., 2015). 
 
CD74 has been implicated as a negative regulator of angiotensin II type 1 
receptor (AGTR1), which plays a fundamental role in regulating blood pressure 
and is therefore involved in hypertension and atherosclerosis. AGTR1 also 
regulates the hormone angiotensin II (AngII) and in so doing, it influences many 
other signal pathways that include the activation of G proteins, protein kinase C, 
tyrosine kinases and mitogen-activated protein kinases (MAPKs). All of these 
functions are reliant on the C-terminal tail of AGTR1, which is expressed in the 
ER and was found to bind to CD74 within this compartment. This interaction 
causes AGTR1 aggregation in the ER and ultimately leads to the proteasomal 
degradation of AGTR1 (Szaszak et al., 2008). This indicates that CD74 also 
plays a role in the regulation of these important signal cascades as well as 
cardiovascular disorders.  
 
The multiple functions of CD74 provide evidence that this protein plays a vital role 
in many different pathways, not only within a single cell, but also from cell to cell. 
Vpu binds to the CD74-ICD within the ER (Hussain et al., 2008), yet many 
downstream consequences of this interaction have not been studied. All of the 
abovementioned functions of CD74 are likely to be influenced by its interaction 
with Vpu, as it has already been shown that the interaction between Vpu and 
CD74 leads to a downregulation in MHCII surface expression, which is naturally 
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followed by reduced antigen expression and ultimately decreases the activation 
of T cells. It is not unreasonable to assume that this binding interaction will also 
impede the role of CD74 in signal transduction. However, it is as yet unclear 
whether Vpu is able to restrain CD74 simply by binding to it and retaining it within 
the ER or if Vpu targets CD74 for degradation.  
 
1.6 Similarities between CD4 and CD74 
Similarities exist between CD74 and CD4 that may suggest that CD74 is possibly 
degraded through Vpu binding in a way similar to that of CD4. First, both CD74 
and CD4 interact with the cytoplasmic domain of Vpu via their own cytoplasmic 
domains (Willey et al., 1994; Hussain et al., 2008), which suggests that CD4 and 
CD74 may bind to the same site on the Vpu cytoplasmic domain. Second, the 
binding interactions between Vpu and CD4 or CD74 respectively both occur 
within the same cellular location, which is the ER (Margottin et al., 1998; 
Belaϊdouni et al., 2007). Third, the ion channel activity of Vpu may play a role in 
influencing intracellular calcium levels and a decrease of calcium within the ER 
leads to an increase in the proteolysis of many ER proteins (Wileman et al., 1991; 
Willey et al., 1992a), which may include both CD4 and CD74. Fourth, the ability 
of Vpu to induce degradation of CD4 requires cytosolic protein polyubiquitination 
machinery that targets lysine residues in the CD4 cytoplasmic domain (Margottin 
et al., 1998; Schubert et al., 1998; reviewed in Andrew and Strebel, 2010). It was 
also shown that serine and threonine residues are ubiquitin sites (Magadan et al., 
2010). Although CD74 does not have threonine, both CD4 and CD74 contain 
lysine and serine residues in their cytoplasmic domains (Schubert et al., 1998; 
Strubin et al., 1984). The presence of potential ubiquitination sites within the 
CD74 cytoplasmic domain indicates that this protein may possibly be targeted for 
ubiquitination. These similarities taken together suggest that the binding sites on 
Vpu for CD4 and CD74 may be closely related which further suggests that Vpu 
may mediate the degradation of CD74 via a similar mechanism to that of CD4, 
i.e. by the ubiquitination of CD74 and subsequent proteasomal degradation. 
  
1.7 Project hypothesis and objectives 
The many important functions of CD74 including the chaperoning of antigen 
presentation and its involvement in cellular signal transduction pathways make 
this protein an attractive target for downregulation by multiple HIV-1 accessory 
proteins, including the Vpu accessory protein. To date, it has been shown that 
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Vpu modulates surface expression of the mature MHCII molecules by interacting 
with CD74 within the ER. However, it is not yet clear whether Vpu only mediates 
downregulation of MCHII by retention of the immature complex within the ER or if 
CD74 itself is downregulated and/or degraded through the binding interaction. As 
mentioned above, there are numerous reasons that suggest that CD74 may be 
targeted for proteasomal degradation similar to that of CD4. Additionally, HIV-1 
has multiple reasons to downregulate CD74 as this host protein is involved in 
numerous important functions. Taking this into account, the hypothesis of this 
study is that the binding of Vpu targets CD74 for proteasomal degradation 
through the recruitment of β-TrCP in a mechanism similar to that of Vpu-
associated CD4 degradation. To this end, the main aim of this study was to 
elucidate the downstream consequences of the HIV-1 Vpu/CD74 binding 
interaction, as compared to Vpu/CD4 degradation, more specifically to elucidate 
whether Vpu mediates the proteasomal degradation of CD74 or if CD74 is merely 
downregulated. This was achieved through the fulfilment of the following 
objectives:  
 Firstly, to establish the binding interaction of HIV-1 subtype B Vpu with 
CD4 and CD74 respectively through the use of in vitro assays;  
 Secondly, to determine the downregulation of both CD4 and CD74 by 
binding to Vpu in a cell based assay;  
 And finally, to investigate the possible mechanism of CD74 
downregulation by the interaction with Vpu, as compared to Vpu mediated 
CD4 proteasomal degradation. 
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CHAPTER TWO: MATERIALS AND 
METHODS 
 
2.1 CD4/CD74 homology study  
The sequence of the CD74 cytoplasmic domain was obtained from UniProt 
(www.uniprot.org; accession number P04233; last updated 16 April 2002). The 
sequence of the CD4 cytoplasmic domain was also obtained from UniProt 
(accession number P01730; last updated 1 November 1988). The PredictProtein 
Server was used to calculate the percentage of secondary structure for the CD4 
cytoplasmic domain and the CD74 cytoplasmic domain, based on amino acid 
sequence using the PROFphd method (Rost et al., 2004; Wrzeszczynski and 
Rost, 2004; Yachdav et al., 2014). The secondary structure was also predicted 
using Discovery Studio 4 (BIOVIA, USA) and compared to the secondary 
structure assigned to each protein by the Dictionary of Protein Secondary 
Structure (DSSP; Kabsch and Sanders, 1983), which is available through the 
Protein Data Bank (PDB; www.rscb.org). The structure of the transmembrane 
and cytoplasmic domains of a cysteine-free CD4 mutant in 
dodecylphosphocholine (DPC) micelles has previously been determined by NMR 
(Wittlich et al., 2010). The co-ordinates of this protein (PDB 2KLU) were uploaded 
to Discovery Studio 4 (BIOVIA, USA) in order to obtain a model structure. A 
representation of the folding of the CD74 cytoplasmic domain was constructed 
using Discovery Studio 4 (BIOVIA, USA) by building the peptide based on the 
amino acid sequence, using the right-handed α-helical conformation. The 
predicted secondary structure was used to determine which sections would be 
unstructured and the location of the α-helix. Hydrophobicity plots of the CD4 and 
CD74 cytoplasmic domains were calculated using Discovery Studio 4 (BIOVIA, 
USA), which makes use of the Kyte and Doolittle hydropathy scale (Kyte and 
Doolittle, 1982) with a default window size of 5. This scale takes both the 
hydrophobicity and the hydrophilicity of each of the amino acid side chains into 
account, in order to determine the average hydropathy within a pre-determined 
window throughout the primary sequence from the N-terminus to the C-terminus. 
Residues with hydropathy values greater than zero are considered to be 
hydrophobic, while those with hydropathy values less than zero are hydrophilic. 
Although secondary structure and protein folding may also be influenced by steric 
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effects between side chains, the hydropathy of a peptide or protein gives an 
estimation of which regions form the interior and which are part of the exterior of 
the peptide or protein, as well as which regions interact with or traverse a 
membrane. Additionally, helical wheels were plotted for the α-helices for the 
cytoplasmic domains of CD4 and CD74 using the program from the RZ Lab 
(http://rzlab.ucr.edu/scripts/wheel/wheel.cgi). A sequence alignment of the CD4 
and CD74 cytoplasmic domains was completed using Discovery Studio 4 
(BIOVIA, USA). This was done using the “Align123” multiple sequence alignment 
method, which is based on the CLUSTAL W program and uses a progressive 
pairwise alignment algorithm. The alignment was done using the “Fast” pairwise 
alignment, which makes use of the FASTA format approach. In order to compare 
these peptides structurally, the primary sequence of the CD74 cytoplasmic 
domain was modelled onto the 3D structure of the CD4 cytoplasmic domain, 
using the co-ordinates PDB 2KLU for CD4. This was done using the “Create 
homology models” tool in Discovery Studio 4 (BIOVIA, USA). Twenty models 
were predicted in this way and the model with the smallest Root Mean Square 
Deviation (RMSD) was selected as the most likely model. An energy minimization 
of the selected model was completed using the CHARMm force field and the 
Generalized born with molecular volume (GBMV) solvent model. The RMSD, 
Discrete optimized protein energy (DOPE) score and total probability density 
function (PDF) energy was calculated after aligning and superimposing the 
minimized model onto the template (2KLU). A Ramachandran plot was generated 
in Discovery Studio 4 (BIOVIA, USA) of the energy minimized model (Lovell et 
al., 2003). A structural alignment of the α-helices of CD4 and CD74 was 
completed by selecting the regions of Met407-Glu416 of CD4 and Met17-Asn26 
of CD74 as tethers and superimposing these regions. The RMSD of this new 
alignment was recalculated. 
 
2.2 National Institutes of Health Reagents 
The reagents listed in Table 2.1 were obtained through the NIH AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH. 
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Table 2.1: Reagents from the NIH AIDS Research and Reference Reagent Program 
used within this study. These reagents were used extensively within this study and the 
NIH AIDS Reagent Program catalogue number, contributors and cited references are 
listed here. 
Catalogue 
Number 
Reagent Contributors Reference 
969 HIV-1NL4-3 Vpu Antiserum K Strebel Maldarelli et al. (1993) 
6444 
HIV-1 Consensus Vpu 
Peptides 
DAIDS, NIAID None 
10076 pcDNA-Vphu 
S Bour and K 
Strebel 
Nguyen et al. (2004) 
11942 
Anti-Vpu Rabbit Antiserum 
(Anti-Vpu_C) 
MH Kraus and 
BH Hahn 
Kraus et al. (2010) 
  
2.3 Culture of U937 and HEK 293T cell lines 
The human macrophage U937 suspension cell line (Highveld Biological, RSA) 
was maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, 
Life Technologies, USA) containing 10% (v/v) foetal calf serum (FCS; Highveld 
Biological, RSA), 20 µg/ml gentamycin sulphate (Highveld Biological, RSA) and 
20 µg/ml penicillin/streptomycin (Highveld Biological, RSA) in a 5% CO2 
environment at 37°C. U937 cells were subsequently used in immunoprecipitation 
experiments and flow cytometry. HEK 293T (ATCC® CRL-11268TM, USA) 
adherent cells were maintained in high glucose Dulbecco’s Modified Eagle’s 
Medium (DMEM) with L-glutamine and sodium pyruvate (Hyclone, Thermo 
Scientific, USA) containing 10% (v/v) FCS (Highveld Biological, RSA) and 20 
µg/ml gentamycin sulphate (Highveld Biological, RSA) as well as 20 µg/ml 
penicillin/streptomycin (Highveld Biological, RSA) in a 5% CO2 environment at 
37°C. HEK 293T cells were routinely used for the expression of recombinant 
Vpu::GFP. Both U937 and HEK 293T cells were grown to confluency before 
culturing. Cells were centrifuged at 500 xg for 5 minutes at 21°C and the cell 
pellet was resuspended in 1 mL of medium. The cell concentration was 
determined using a Countess Automated Cell Counter (Life Technologies, USA). 
Cells were seeded at a density of 1 x 105 per ml. 
 
2.4 Construction of Vpu::GFP and Vpu phosphorylation mutants 
Bacterial cells (One Shot® TOP10 Chemically Competent E. coli, Life 
Technologies, USA) were transformed with plasmid DNA (adapted from Studier 
and Moffat, 1986 and Froger and Hall, 2007). Briefly, bacterial cells were 
incubated with 1 µl of 10 ng/µl pcDNA-Vphu (NIH catalogue number 10076; 
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Table 2.1) on ice for 30 minutes, followed by heat shock at 42°C for 45 seconds 
and a further 2 minutes on ice. Following this, 500 µl SOC medium (Luria-Bertani 
[LB] broth [Conda Pronadisa Molecular Biology, Spain]; 2.5 ml of 1 M KCl 
[Associated Chemical Enterprises, RSA]; 10 ml of 1 M MgCl2 [Sigma Aldrich, 
USA]; 20 ml of 1 M glucose [Minema Chemicals, RSA]) was added and the 
bacteria were incubated at 37°C and shaken at 250 rpm for 1 hour before being 
spread onto a LB/ampicillin (LB Agar, Lennox, Conda Pronadisa Molecular 
Biology, Spain; 100 µg/ml ampicillin sodium salt, Melford Laboratories Ltd, UK) 
plate and left to grow at 37°C for approximately 16 hours. Random colonies were 
selected and transferred to sterile LB Broth (Conda Pronadisa Molecular Biology, 
Spain) medium with a final concentration of 100 µg/ml ampicillin (Melford 
Laboratories Ltd, UK) for growth overnight, at 37ºC and shaking at 250 rpm. Total 
plasmid DNA was isolated from the bacteria using the Qiagen Plasmid Maxiprep 
Kit, as per manufacturer’s instructions (Qiagen, Netherlands). The Vpu fragment 
was PCR amplified with Ex Taq DNA polymerase (0.5 µl of a stock of 5 units/µl; 
TaKaRa, Japan) using the following primers (Inqaba Biotechnical Industries, 
RSA): Vpu FwD, 5’ GCCATGGTGCCCATTATTGTCG 3’ and Vpu Rev, 5’ 
CAGGTCGTCAATGTCCCAG 3’.  
 
Single and double restriction digests of the plasmid were performed using the 
MscI and Acc65I restriction enzymes (Fermentas Life Sciences, Thermo 
Scientific, USA). The Vpu fragment was excised from a 1% (w/v) agarose gel 
after staining with SYBR Gold (Invitrogen Molecular Probes, Life Technologies, 
USA). This fragment was isolated using the Strataprep DNA Gel Extraction Kit, 
as per manufacturer’s instructions (Stratagene, Agilent Technologies, USA) and 
ethanol precipitated to concentrate each sample. The amplified fragment was 
then cloned into the pcDNATM 6.2/C-EmGFP TOPO adapted vector (Invitrogen 
Vivid Colours, Life Technologies, USA) as per manufacturer’s instructions, and 
used to transform bacterial cultures as described above. Site-directed 
mutagenesis was used to remove a stop codon between the Vpu and GFP 
sequences using the QuikChange Lightning Site-Directed Mutagenesis kit, as per 
manufacturer’s instructions (Agilent Technologies, USA) using the following 
primers (Inqaba Biotechnical Industries, RSA): Fwd, 5’ 
GGGACATTGACGACCTGTGCTACAGAAAAATTGTGG 3’ and Rev, 5’ 
CCACAATTTTTCTGTAGCACAGGTCGTCAATGTCCC 3’. The plasmid, 
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designated pVpu::GFP, was then sequenced (automated sequencing at Inqaba 
Biotechnical Industries, RSA) to confirm the correct sequence of the fusion 
protein. 
 
Site-directed mutagenesis was then used to produce two Vpu::GFP 
phosphorylation mutants. The first mutant carried a mutation at the Ser52 residue 
(pVpu-SM) while the second mutant carried mutations at both serine residues, 
namely Ser52 as well as Ser56 (pVpu-DM). In both mutants, the serine residues 
were replaced with alanine. These mutations were generated using the 
QuikChange Lightning Site-Directed Mutagenesis kit, as per manufacturer’s 
instructions (Agilent Technologies, USA) with the following primers (Inqaba 
Biotechnical Industries, RSA) for pVpu-SM: 5’ 
CGCGCCGAGGACGCCGGCAACGAGAGCGAGGGCGAG 3’ and 5’ 
CTCGCCCTCGCTCTCGTTGCCGGCGTCCTCGGCGCG 3’, and for pVpu-DM: 
5’ CGCGCCGAGGACGCCGGCAACGAGGCCGAGGGCGAG 3’ and 5’ 
CTCGCCCTCGGCCTCGTTGCCGGCGTCCTCGGCGCG 3’. These mutant 
plasmids were used to transform bacterial cultures as described above and the 
presence of the mutations were confirmed through sequencing (Inqaba 
Biotechnical Industries, RSA). 
 
All plasmids with the correct sequences were replicated in bacterial cells in order 
to increase the plasmid yield. E. coli cells were transformed as described above 
with each plasmid. Random colonies were selected and grown overnight in sterile 
LB Broth (Conda Pronadisa Molecular Biology, Spain) medium with a final 
concentration of 100 µg/ml ampicillin (Melford Laboratories Ltd, UK), at 37ºC and 
shaking at 250 rpm. Total plasmid DNA was isolated from the bacterial cultures 
using the Qiagen Plasmid Maxiprep Kit (Qiagen, Netherlands) according to the 
manufacturer’s instructions.  
 
2.5 Expression and purification of Vpu::GFP 
Optimal mammalian expression and purification conditions of recombinant 
Vpu::GFP fusion protein were established. HEK 293T cells were plated into 6-
well microtiter plates (Becton Dickinson Labware, USA) at a concentration of 0.25 
x 106 /ml 24 hours prior to being transfected with 5 µg of the pVpu::GFP construct 
using Lipofectamine LTX with PlusTM reagent, following the manufacturer’s 
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instructions (Life Technologies, USA) for protein expression. Briefly, 5 µg of 
plasmid was diluted in 100 µl of DMEM with 2.5 µl of the Plus reagent. In a 
separate tube, 8.75 µl of Lipofectamine was diluted in 100 µl of DMEM. The 
diluted plasmid and Lipofectamine solutions were added together and incubated 
for 5 minutes at room temperature before being added to the 70-80% confluent 
plated cells in a drop-wise manner. Fluorescent images were taken using the 
Floid® cell imaging station (Life Technologies, USA) and the Olympus CKX41 
fluorescent microscope (Wirsam Scientific and Precision Equipment, (Pty) Ltd, 
RSA).  
 
Transfected cells were lysed 48 hours after transfection using the Mem-PER 
Eukaryotic Membrane Protein Extraction kit (Pierce, Thermo Scientific, USA) 
according to the manufacturer’s instructions. Briefly, cells were harvested and 
washed with 1 ml of sterile phosphate buffered saline (PBS; Sigma Aldrich, USA) 
and then resuspended in 150 µl of Reagent A for 10 minutes at room 
temperature, with occasional vortexing. Reagent B and C were diluted 1:2 and a 
total of 450 µl of the diluted reagents was added to the cells and incubated for 30 
minutes on ice, vortexing every 5 minutes. The samples were centrifuged at 10 
000 xg for 3 minutes at 4°C. The pellet fraction was solubilized as previously 
described (Schubert et al., 1998), i.e. the pellet was dissolved in 2% (w/v) sodium 
dodecyl sulphate (SDS; Fluka, Sigma Aldrich, USA) with 50 µg/ml DNAse I 
(Sigma Aldrich, USA) and heated at 95°C for 20 minutes. After solubilisation, the 
sample was centrifuged at 500 xg for 15 minutes to remove the cell debris. The 
supernatant was decanted and diluted in 50 mM Tris (Melford Laboratories Ltd, 
UK), 300 mM NaCl (Associated Chemical Enterprises, RSA) and 0.1% (w/v) 
Triton X-100 (Promega Corporation, USA). The pellet was resuspended in 50 mM 
Tris (Melford Laboratories Ltd, UK), 300 mM NaCl (Associated Chemical 
Enterprises, RSA) and 0.1% (w/v) Triton X-100 (Promega Corporation, USA). 
Both the supernatant and the pellet fractions were separated using SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) using the Bio-Rad Mini 
PROTEAN TG-X pre-cast stain-free gels, 4-15%. Gels were visualised using the 
ChemiDocTM MP System (Bio-Rad, USA). Proteins were transferred to a 
polyvinylidene difluoride (PVDF) membrane using mini PVDF transfer stacks (Life 
Technologies, USA) with the Invitrogen iBlot (Life Technologies, USA) according 
to the manufacturer’s instructions for a standard 7 minute protocol. After blocking 
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in 1X Tris buffered saline (TBS; 20 mM Tris [Melford Laboratories Ltd, UK], 140 
mM NaCl [Associated Chemical Enterprises, RSA], pH 7.6) containing 5% (w/v) 
casein peptone (Conda Pronadisa Molecular Biology, Spain) for 1 hour at room 
temperature, the membrane was washed three times with 1X TBS containing 
0.1% (w/v) Tween 20 (1X TBST; Sigma Aldrich, USA) and then incubated with 10 
000X diluted rabbit anti-Vpu antibody (subtype B; NIH catalogue number 969; 
Table 2.1) for 1 hour at room temperature. Following this, the membrane was 
again washed three times with 1X TBST for 10 minutes each before incubation 
with 20 000X diluted horseradish peroxidase (HRP)-labelled goat anti-rabbit IgG 
(KPL, USA) for 1 hour at room temperature. After washing again as described, 
the membrane was incubated with the substrate solution for 5 minutes 
(SuperSignal West Pico Chemiluminescent Substrate for detection of HRP, 
Thermo Scientific, USA) and visualised using the ChemiDocTM MP System and 
Image LabTM software (Bio-Rad, USA).  
 
A second western blot was completed with 500X diluted mouse anti-GFP 
antibody (purified mouse monoclonal IgG, R&D Systems, USA) and 1000X 
diluted rabbit anti-mouse IgG (peroxidase conjugated affinity purified anti-mouse 
IgG, gamma chain, Rockland, USA) to confirm the presence of the GFP tag. A 
third western blot was completed with 1000X diluted mouse anti-phosphoserine 
antibody (Santa Cruz Biotechnology Inc., USA) and 2000X diluted HRP-labelled 
goat anti-mouse IgM (Santa Cruz Biotechnology Inc., USA) to indicate the 
phosphorylation of the serine residues. The NanoDrop spectrophotometer 
(Thermo Scientific, USA) was used to determine the absorbance to calculate the 
concentration of recombinant Vpu::GFP. The protein was aliquoted and stored at 
-80°C until further use. 
 
2.6 In vitro assays for protein-protein interactions 
CD74 (MHRRRSRSCREDQKPVMDDQRDLISNNEQL; N-terminal residue 
positions 1-30), CLIP (MRMATPLLM; residue positions 107-115) and CD4 
(RQAERMSQIKRLLSEKKTCQCPHRFQKTC; C-terminal residue positions 427-
455) peptides were synthesised by the BIOPEP Peptide Laboratory (Department 
of Biochemistry, Stellenbosch University, RSA). Enzyme-linked immunosorbent 
assays (ELISAs) were set up and used to investigate the binding between 
recombinant Vpu::GFP and CD4, CD74 or CLIP peptides (adapted from Hussain 
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et al., 2008). The Vpu::GFP fusion protein (400 ng per well) was plated in coating 
buffer (0.05 M Na2CO3 [Sigma Aldrich, USA], 0.05 M NaHCO3 [Saarchem, Merck 
Chemicals, USA]; 0.1% (w/v) NaN3 [Sigma Aldrich, USA], pH 9.6), and incubated 
overnight at 4°C. After washing three times with 1X TBS and blocking with 5% 
(w/v) casein peptone (Conda Pronadisa Molecular Biology, Spain) for 2 hours at 
room temperature, plates were washed again with 1X TBS and incubated with 
CD74, CD4 or CLIP peptides (500 ng per well) and incubated overnight at 4°C. 
After washing once with 1X TBS, plates were incubated with 1000X diluted rabbit 
anti-Vpu antibody (subtype B, NIH catalogue number 969; Table 2.1) for 2 hours 
at room temperature. Plates were then washed three times with 1X TBST and 
incubated with 2000X diluted goat anti-rabbit IgG peroxidase labelled antibody 
(KPL, USA) for 90 minutes at room temperature before visualising with the 
substrate, 3,3’,5,5’-tetramethylbenzidine liquid (TMB; Life Technologies, USA). 
The absorbance was measured 1 hour after the addition of the substrate at 650 
nm using the xMark microplate spectrophotometer (Bio-Rad, USA). Controls 
were included in all plates: wells containing coating buffer only, wells that were 
only incubated with primary antibody and finally wells that were only incubated 
with secondary antibody. 
  
The ELISA described above was repeated using 500X diluted mouse anti-GFP 
(purified mouse monoclonal IgG, R&D Systems, USA) followed by 1000X diluted 
rabbit anti-mouse IgG (peroxidase-conjugated affinity purified anti-mouse IgG, 
gamma chain, rabbit, Rockland, USA) or 5000X diluted rabbit anti-CD74 (Abcam, 
UK) followed by 10 000X diluted goat anti-rabbit IgG peroxidase labelled antibody 
(KPL, USA), or 5000X diluted rabbit anti-CD4 (Sigma Aldrich, USA) followed by 
10 000X diluted goat anti-rabbit IgG peroxidase labelled antibody (KPL, USA).  
 
Once binding had been established, a dose response study was also set up with 
100, 250, 500, 1000, 5000 and 10 000 ng of CD74 in order to determine the half 
maximal inhibitory concentration (IC50). The IC50 was calculated using Origin 
software (OriginLab, USA). To add to this, a competitive inhibition assay was 
completed in which 400 ng of Vpu::GFP was incubated with different 
concentrations of CD74 (250, 500, 1000, 5000 and 10 000 ng) before being 
incubated with the coated CD4 peptide (500 ng) in order to determine if CD4 and 
CD74 bind to the same/overlapping site on Vpu.  
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Furthermore, an assay was completed by plating with a set of 19 overlapping Vpu 
peptides (Table 2.2; NIH catalogue number 6444) at 500 ng each. Initially, these 
overlapping Vpu peptides were not incubated with any secondary proteins or 
peptides, i.e. CD74 or CD4 peptides, and were incubated directly with 1000X 
diluted rabbit anti-Vpu antibody (subtype B, NIH catalogue number 969) with 
2000X diluted goat anti-rabbit IgG peroxidase labelled antibody (KPL, USA), or 
subtype C rabbit anti-Vpu antibody (NIH catalogue number 11942) with 10 000X 
diluted goat anti-rabbit IgG peroxidase labelled antibody (KPL, USA), or a 
different source of 1000X diluted rabbit anti-Vpu antibody (Abcam, UK) with 
2000X diluted goat anti-rabbit IgG peroxidase labelled antibody (KPL, USA). 
Following this, the overlapping Vpu peptides were incubated with 500 ng of 
CD74, CD4 or CLIP after coating, as described above, and incubated with either 
the subtype B or subtype C rabbit anti-Vpu antibodies, or with 5000X diluted 
rabbit anti-CD4 (Sigma Aldrich, USA) followed by 10 000X diluted goat anti-rabbit 
IgG peroxidase labelled antibody (KPL, USA). Wash steps and incubation times 
were carried out as for all previously described assays.  
 
Table 2.2: Amino acid sequences of the HIV-1 Consensus Vpu Peptides, obtained 
from the NIH AIDS Research and Reference Reagent Program. The set contains 19 
overlapping peptides with the first 6 peptides comprising 9 residues each and the rest 
comprising 15 residues each, with the exception of the last peptide which comprises 13 
residues. 
 
Cat # AA Code 
 
Cat # AA Code 
1 6423 MQSLQILAI 11 5982 RKIDRLIDRIRERAE 
2 6424 QILAIVALV 12 5983 RLIDRIRERAEDSGN 
3 6425 IVALVVAAI 13 5984 RIRERAEDSGNESEG 
4 6426 VVAAIIAIV 14 5985 RAEDSGNESEGDQEE 
5 6427 IIAIVVWTI 15 5986 SGNESEGDQEELSAL 
6 6428 VVWTIVFIE 16 5987 SEGDQEELSALVEMG 
7 5978 VVWTIVFIEYRKILR 17 5988 QEELSALVEMGHHAP 
8 5979 IVFIEYRKILRQRKI 18 5989 SALVEMGHHAPWDVD 
9 5980 EYRKILRQRKIDRLI 19 5990 EMGHHAPWDVDDL 
10 5981 ILRQRKIDRLIDRIR 
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A set of 10-mer and of 15-mer overlapping CD74 cytoplasmic domain peptides 
were obtained from the BIOPEP Peptide Laboratory (Department of 
Biochemistry, Stellenbosch University – Table 2.3). Both sets were used in in 
vitro assays (ELISAs) as described above (500 ng/peptide) and tested in 
conjunction with both 400 ng of the full-length Vpu::GFP fusion protein as well as 
400 ng of each of the 19 overlapping Vpu peptides (NIH catalogue number 
6444), following wash steps and incubation times as described above for the 
subtype B rabbit anti-Vpu antibody (NIH catalogue number 969) and a different 
source of rabbit anti-Vpu antibody (Abcam, UK). 
 
Finally, the coated Vpu::GFP protein (400 ng) was incubated with consecutive 
combinations of the 10-mer overlapping CD74 peptide set in the same way as 
described above, using the subtype B rabbit anti-Vpu antibody (NIH catalogue 
number 969; Table 2.1). The total concentration of each combination of peptides 
was equal to that of the single peptides. 
 
Table 2.3: Amino acid sequences of the nine CD74 10-mer and 15-mer overlapping 
peptides that were produced and used in the ELISA studies. Each of the sets was 
generated from the CD74 cytoplasmic domain peptide.  
10-mer 15-mer 
Name Sequence Name Sequence 
CDPep10.1 MHRRRSRSCR CDPep15.1 MHRRRSRSCREDQKP 
CDPep10.2 SRSCREDQKP CDPep15.2 SRSCREDQKPVMDDQ 
CDPep10.3 EDQKPVMDDQ CDPep15.3 EDQKPVMDDQRDLIS 
CDPep10.4 VMDDQRDLIS CDPep15.4 VMDDQRDLISNNEQL 
CDPep10.5 RDLISNNEQL 
  
 
In all the ELISAs described above, duplicate samples were included in each plate 
for each sample type and each plate was repeated three times, making a total of 
six replicates per sample. The six replicates were used to calculate averages and 
standard deviations. 
 
2.7 Immunoprecipitations 
To validate the ELISA data, the binding of expressed Vpu::GFP to native CD74 in 
U937 cells was evaluated by immunoprecipitation experiments. U937 cells were 
cultured as described in section 2.3. Cells were optimally transfected using the 
Neon Electroporation system (Life Technologies, USA) following the 
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manufacturer’s instructions. Briefly, cells were harvested after treatment and 
washed with Dulbecco’s PBS (Highveld Biological, RSA) and then resuspended 
in 1 ml of Resuspension buffer R from the 100 µl Neon Electroporation kit (Life 
Technologies, USA) to a concentration of 2 x 107 cells per ml. Samples were 
prepared containing either 10 µg of a control GFP plasmid, pMax (Lonza, USA), 
or 10 µg of pVpu::GFP plasmid and 100 µl of the resuspended cells. 
Untransfected samples did not contain any plasmid. Each sample was 
electroporated at 1400 volts with a pulse width of 20 ms, three pulses per 
sample. Each sample was then placed into 2 ml of filter sterilized RPMI medium 
(Gibco, Life Technologies, USA) containing 10% (v/v) FCS (Highveld Biological, 
RSA) in a 6-well tissue culture plate and incubated at 37°C with 5% CO2. 
 
Cells were harvested 24 hours post transfection and washed with Dulbecco’s 
PBS (Highveld Biological, RSA). Following this, cells were resuspended in lysis 
buffer (150 mM NaCl [Associated Chemical Enterprises, RSA], 50 mM (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES; Sigma Aldrich, USA], 1 
mM ethylenediaminetetraacetic acid [EDTA; Sigma Aldrich, USA], 0.5% (w/v) 
Triton X-100 [Promega Corporation, USA], 0.5% (v/v) Igepal [Sigma Aldrich, 
USA], 1X protease cocktail inhibitor [Sigma Aldrich, USA], pH 7.4) and sonicated 
twice using a sonicator probe (Labsonic M, Sartorius, Germany) for 1 minute 
each on ice at 60% amplitude and a 0.6 cycle. Cell lysates were incubated with 1 
µg of mouse anti-CD74 antibody (BD Pharmingen, USA) at 4°C for 1 hour with 
rotational agitation. Protein G Dynabeads (Life Technologies, USA) were washed 
with the abovementioned lysis buffer, and 50 µl of beads were added to the 
lysate-antibody mix and incubated at 4°C for 90 minutes with rotational agitation. 
Following incubations, the beads were washed 5 times with lysis buffer and 
resuspended in denaturing SDS sample buffer (Bio-Rad, USA) and boiled for 5 
minutes. The beads were removed using the DynaMag magnet (Life 
Technologies, USA) and the samples were analysed by SDS-PAGE using the 
Bio-Rad Mini PROTEAN TG-X pre-cast stain-free gels, 4-15%. Gels were 
visualised using the ChemiDocTM MP System (Bio-Rad, USA) and a western blot 
was completed as described in section 2.5 above. The primary antibody used 
was 1000X diluted mouse anti-CD74 (BD Pharmingen, USA) followed by 2000X 
diluted HRP-labelled rabbit anti-mouse IgG (Rockland, USA) before substrate 
was added.  
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2.8 Flow cytometry 
The ability of expressed Vpu::GFP to downregulate CD4, MHCII and CD74 in 
U937 cells was investigated following the establishment and optimization of a 
standard flow cytometry protocol for cell treatment, staining and analysis. U937 
cells were sub-cultured to a concentration of 5 x 105 cells per ml into T75 culture 
flasks. Three sets of cells were prepared and were either left untreated, treated 
with 20 ng/ml of phorbol 12-myristate 13-acetate (PMA) or treated with 20 ng/ml 
of interferon-γ (IFN-γ) for 24 hours at 37°C, 5% CO2. PMA was used to 
differentiate the U937 cells to a macrophage-like phenotype which may have an 
effect on MHCII expression (Tosi et al., 2002; Baek et al., 2009). IFN-γ has been 
reported to upregulate the expression of the MHCII I-A beta gene (Celada and 
Maki, 1991) and was used to investigate the effect of this activator on MHCII and 
CD74 expression. Transfection conditions were optimized and completed using 
the Neon Electroporation system (Life Technologies, USA) following the 
manufacturer’s instructions as described in section 2.7. However, cells were 
transfected at a concentration of 1 x 107 cells per ml. Samples were prepared 
containing 10 µg of pVpu::GFP, pVpu-SM or pVpu-DM plasmid and 100 µl of the 
resuspended cells. Mock-transfected samples did not contain any plasmid. The 
samples were then electroporated and incubated as described before (section 
2.7). 
  
Cells were harvested 24 hour and 48 hours post-transfection and washed with 1 
ml PBS containing 1% (w/v) bovine serum albumin (BSA; Highveld Biological, 
RSA) and 0.1% (w/v) NaN3 (Sigma Aldrich, USA). Cells were permeabilized in 
the dark with Cytofix/Cytoperm buffer (BD Pharmingen, USA) for 20 minutes at 
4°C and washed twice with 1X diluted Perm/Wash buffer (BD Pharmingen, USA). 
Following permeabilization, cells were incubated with 5 µg of mouse anti-CD74 
(BD Pharmingen, USA), mouse anti-CD4 (Sigma Aldrich, USA) or fluorescein 
isothiocyanate (FITC)-labelled mouse anti-HLA-DR (Sigma Aldrich, USA) for 30 
minutes at room temperature in the dark and then washed twice with 1X diluted 
Perm/Wash buffer (BD Pharmingen, USA). Cells that were stained for CD4 and 
CD74 levels were incubated with 1 µg of phycoerythrin (PE)-labelled goat anti-
mouse Ig (BD Pharmingen, USA) for 30 minutes at room temperature in the dark. 
After a final washing step with 1X diluted Perm/Wash buffer (BD Pharmingen, 
USA), cells were resuspended in 0.5% (w/v) paraformaldehyde (Sigma Aldrich, 
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USA) before analysis. The stained cells were acquired (5000 events per sample) 
using a Guava easyCyteTM two laser flow cytometer (Merck Millipore, USA) at a 
medium flow rate of 0.59 µl per second. Data analysis was completed using the 
guavaSoft software, version 2.7 (Merck Millipore, USA).  
 
2.9 Statistical analyses 
All general statistical analyses such as the calculation of averages and standard 
deviations were performed using Excel (Microsoft, USA). The calculation of p 
values was done using the Simple Interactive Statistical Analysis (SISA) website, 
www.quantitativeskills.com/sisa. Six replicates were completed per sample set for 
each method. For ELISAs, absorbance values were used to calculate averages 
and standard deviations and for flow cytometry, mean fluorescence was used to 
calculate averages and standard deviations. 
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CHAPTER THREE: RESULTS 
 
3.1 Peptide characterization 
3.1.1 Predicted structure and peptide properties 
In order to compare CD4 and CD74, the PredictProtein Server 
(www.predictprotein.org/) was used to calculate the percentage of secondary 
structure for the cytoplasmic domains of CD4 and CD74, based on amino acid 
sequence (Rost et al., 2004; Wrzeszczynski and Rost, 2004; Yachdav et al., 
2014). The cytoplasmic domain of CD74 is mostly unstructured, with 23.33% of 
α-helix, while the cytoplasmic domain of CD4 has 48.28% of α-helix. The majority 
of residues in the CD4 and CD74 cytoplasmic domains have more than 16% of 
their surfaces exposed (89.66% and 93.33%, respectively) and were not found to 
contain β-sheets. The secondary structure was predicted using Discovery Studio 
4 and compared to the secondary structure assigned to each protein by the 
DSSP (Kabsch and Sanders, 1983), which is available through the PDB 
(www.rscb.org). However, the only structure available on the PDB was for CD4. 
The secondary structure of the CD74 cytoplasmic domain was calculated purely 
on amino acid sequence as this peptide has not been crystallized yet.  
 
Figure 3.1 shows the predicted secondary structure for the transmembrane and 
cytoplasmic domains of CD4 using the 2KLU co-ordinates; Figure 3.1A was 
determined using the DSSP (Kabsch and Sanders, 1983) while Figure 3.1B was 
predicted using Discovery Studio 4. Although the same co-ordinates and 
sequence of CD4 was used for both the DSSP and Discovery Studio, a 
discrepancy exists between the results. The DSSP predicts an α-helix that is 7 
residues long (Q409-S415) while Discovery Studio predicts an α-helix that is 14 
residues long (R401-L414). The co-ordinates for CD4 (2KLU) were uploaded to 
Discovery Studio to obtain a model of this peptide (Figure 3.1C). The HIV-1 Vpu 
susceptibility domain (residues 427-455) which is located within the cytoplasmic 
domain (residues 419-458) is indicated by a black box in Figure 3.1 A, B and C. 
The cytoplasmic α-helix from Figure 3.1A was used to plot the helical wheel in 
Figures 3.1D using the program from the RZ Lab 
(http://rzlab.ucr.edu/scripts/wheel/wheel.cgi), indicating the hydrophobic resides 
grouped together on the right side of the helix. This program shows charged 
residues in light blue, with positively charged residues displayed as pentagons 
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and negatively charged residues displayed as triangles. Hydrophilic residues are 
shown as red/orange circles, with the deepness of the red colour being 
proportional to the level of hydrophilicity; hydrophobic residues are shown as 
green diamonds, again with the intensity of the colour proportional to the level of 
hydrophobicity. 
  
 
Figure 3.1: Predicted secondary structure of the T-cell surface glycoprotein CD4. 
The peptide sequence was obtained from the Protein Data Bank, using 2KLU co-
ordinates (www.rscb.org). The HIV-1 Vpu susceptibility region (indicated by the black 
boxes) is located in the cytoplasmic domain and appears to have a short α-helix. The 
secondary structure is A) assigned from the DSSP and B) predicted by Discovery Studio 
4. C) Model of CD4 transmembrane and cytoplasmic domains generated by Discovery 
Studio 4, using co-ordinates 2KLU. D) Helical wheel of the α-helix in the cytoplasmic 
domain of CD4 indicating the hydrophobic residues in green clustered on the right side of 
the helix with the charged and hydrophilic (blue and red/orange, respectively) residues 
arranged towards the left. This was determined using RZ lab 
(http://rzlab.ucr.edu/scripts/wheel/wheel.cgi). 
 
The sequence of the CD74 cytoplasmic domain was obtained from UniProt 
(P04233) and the secondary structure was predicted only using Discovery Studio 
4 based on the amino acid sequence as there is no resolved structure on the 
PDB (Figure 3.2A). This peptide is predicted to contain one α-helix that is 5 
residues long (Q20-I24), while the remaining sections are unstructured. A 
representation or model of the folding of the cytoplasmic domain of CD74 was 
constructed using Discovery Studio 4 (Figure 3.2B), while the helical wheel of the 
A 
B 
C D 
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predicted α-helix in the cytoplasmic domain of CD74 is shown in Figure 3.2C. 
This indicates a mix of the hydrophobic and hydrophilic residues on one side, and 
a collection of charged residues on the opposite side. However, as mentioned 
above, this helix was predicted on primary sequence alone without taking 3D 
structure into account. 
 
 
Figure 3.2: The predicted secondary structure of the CD74 cytoplasmic domain. A) 
The secondary structure was determined using Discovery Studio 4 from the sequence 
obtained from UniProt, identifier: P04233 (www.uniprot.org). This peptide was predicted 
to have a small, 5-residue α-helix, with the rest unstructured. B) Model of CD74 
cytoplasmic domain predicted using Discovery Studio 4. The secondary structure was 
predicted based on the amino acid sequence from (A) and this was then used to predict 
the folding of the peptide. C) Helical wheel of the α-helix in the cytoplasmic domain of 
CD74 using RZ lab (http://rzlab.ucr.edu/scripts/wheel/wheel.cgi) indicating that the 
hydrophobic (green) and hydrophilic (red) residues clustered together opposite to the 
charged residues (blue), possibly due to the aqueous environment this peptide lies in. 
 
The hydrophobicity plots of CD4 and CD74 were calculated with a default window 
size of 5 using Discovery Studio 4, which makes use of the Kyte and Doolittle 
hydropathy scale (Kyte and Doolittle, 1982). Figure 3.3 shows the hydrophobicity 
plots for A) the cytoplasmic domain of CD4 and B) the cytoplasmic domain of 
CD74. In Figure 3.3A, the CD4 cytoplasmic domain is largely hydrophilic, as 
expected. The cytoplasmic domain of CD74 (Figure 3.3B) also appears to be 
mostly hydrophilic, with small hydrophobic regions. It was expected that both of 
these peptides would be mostly hydrophilic as this domain of CD74 lies within the 
aqueous cytoplasm.  
B 
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Figure 3.3: Hydrophobicity plots calculated for each of the peptides. A) The 
cytoplasmic domain of CD4 and B) the CD74 cytoplasmic domain were both found to be 
largely hydrophilic as indicated by the low hydrophobicity. 
 
3.1.2 Sequence and structural alignment of CD4 and CD74 
CD4 and CD74 were compared in terms of primary sequence. This was done by 
an amino acid sequence alignment of the cytoplasmic domains of CD4 and CD74 
in Discovery Studio 4, using the “Align123” multiple sequence alignment method, 
which is based on the CLUSTAL W program (Figure 3.4). The CLUSTAL W 
program aligns sequences using a progressive pairwise alignment algorithm. The 
alignment was done using the “Fast” pairwise alignment, which makes use of the 
FASTA format approach and is reportedly less accurate than the “Slow” pairwise 
alignment, which makes use of the dynamic programming approach. However, 
both programs were used for the alignment and yielded the same result of 25.6% 
residue identity and 44.2% residue similarity, indicating minimal sequence 
conservation. 
 
 
 
 
A 
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CD4 
CD74 
 
Figure 3.4: Amino acid sequence alignment of the cytoplasmic domains of CD4 and 
CD74. There is a residue identity of 25.6% and a residue similarity of 44.2% between 
CD4 and CD74. Colour intensity indicates the level of similarity.  
  
Although there is little similarity between the cytoplasmic domains of CD4 and 
CD74 in terms of primary structure, this does not necessarily indicate that they 
will be different in terms of secondary structure. In order to compare these 
peptides structurally, the primary sequence of CD74 was modelled onto the 3D 
structure of CD4. This was done using the “Create homology models” tool in 
Discovery Studio 4. Twenty models were predicted in this way and the model with 
the smallest RMSD was selected as the most likely model. The RMSD was 
calculated after aligning and superimposing each of the 20 models onto the 
template (2KLU) and the model shown in Figure 3.5A has an RMSD of 3.296 Å, a 
DOPE score of -1278.71 and PDF total energy of 232.684 after energy 
minimization, showing an overall structural similarity. A Ramachandran plot of the 
CD74 model was generated using Discovery studio 4 (Figure 3.5B) and indicates 
no residues with conformational constraints, which verifies the probability of the 
CD74 model. Owing to the difficulty in comparing unstructured regions of proteins 
due to the disordered nature of these regions, a further comparison was made of 
the α-helices only (Figure 3.5C) for Met17 – Asn26 of CD74 and Met407 – 
Glu416 of CD4. This superimposition yielded a more favourable RMSD value of 
1.437 Å, indicating that the α-helices within the cytoplasmic domains of CD4 and 
CD74 are similar.  
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Figure 3.5: Homology model of the CD74 cytoplasmic domain against the CD4 
cytoplasmic domain. A) The primary sequence of CD74 (grey and red) was modelled 
against the cytoplasmic domain of CD4 as a template (blue) yielding an RMSD of 3.296 
Å. B) Ramachandran plot of the predicted model indicating that all residues lie within the 
“core” and “allowed” regions, signified by green points for each residue. C) 
Superimposition of the α-helices of CD4 and CD74 with an RMSD of 1.437 Å. 
 
3.2 Sequencing and expression of Vpu::GFP in HEK 293T cells 
A recombinant pVpu::GFP plasmid was successfully constructed using the 
pcDNA-Vphu plasmid insert, and subsequently cloning the vpu fragment into the 
pcDNATM 6.2/C-EmGFP TOPO vector. This recombinant plasmid was amplified, 
isolated and nucleotide sequence analysis confirmed that the vpu fragment had 
successfully been cloned in frame with the EmGFP (Figure 3.6). This plasmid 
was subsequently used to generate two Vpu phosphorylation mutants for 
A B 
C 
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subsequent analyses. The first mutant (Vpu-SM) contained the replacement of 
the first serine residue with alanine at position 52 while the second mutant (Vpu-
DM) had both serine residues replaced with alanine at positions 52 and 56, as 
determined by nucleotide sequence analysis. These residues are underlined and 
the alanine codons are indicated in pink in Figure 3.6 below.  
 
A. 
    ATGGTGCCCA TTATTGTCGC CATTGTGGCC CTGGTGGTCG CCATTATTAT  50 
TGCCATTGTG GTGTGGAGCA TTGTGATTAT TGAGTACCGC AAGATTCTGC  100 
GCCAGCGCAA GATTGACCGG TTGATTGACC GCCTGATTGA GCGCGCCGAG  150 
               GCC          GCC 
GACAGCGGCA ACGAGAGCGA GGGCGAGGTG AGCGCTCTGG TGGAGATGGG  200 
CGTGGAGATG GGCCACCACG CCCCCTGGGA CATTGACGAC CTGTGCTACA  250 
GAAAAATTGT GGGTCACAGT CTATTATGGA AGGGCGAATT CGACCCAGCT  300 
TTCTTGTACA AAGTGGTTGA TGCTGTTAAC ATGGTGAGCA AGGGCGAGGA  350 
GCTGTTCACC GGGGTGGTGC CCATCCTGGT CGAGCTGGAC GGCGACGTAA  400 
ACGGCCACAA GTTCAGCGTG TCCGGCGAGG GCGAGGGCGA TGCCACCTAC  450 
GGCAAGCTGA CCCTGAAGTT CATCTGCACC ACCGGCAAGC TGCCCGTGCC  500 
CTGGCCCACC CTCGTGACCA CCTTCACCTA CGGCGTGCAG TGCTTCGCCC  550 
GCTACCCCGA CCACATGAAG CAGCACGACT TCTTCAAGTC CGCCATGCCC  600 
GAAGGCTACG TCCAGGAGCG CACCATCTTC TTCAAGGACG ACGGCAACTA  650 
CAAGACCCGC GCCGAGGTGA AGTTCGAGGG CGACACCCTG GTGAACCGCA  700 
TCGAGCTGAA GGGCATCGAC TTCAAGGAGG ACGGCAACAT CCTGGGGCAC  750 
AAGCTGGAGT ACAACTACAA CAGCCACAAG GTCTATATCA CCGCCGACAA  800 
GCAGAAGAAC GGCATCAAGG TGAACTTCAA GACCCGCCAC AACATCGAGG  850 
ACGGCAGCGT GCAGCTCGCC GACCACTACC AGCAGAACAC CCCCATCGGC  900 
GACGGCCCCG TGCTGCTGCC CGACAACCAC TACCTGAGCA CCCAGTCCGC  950 
CCTGAGCAAA GACCCCAACG AGAAGCGCGA TCACATGGTC CTGCTGGAGT  1000 
TCGTGACCGC CGCCGGGATC ACTCTCGGCA TGGACGAGCT GTACAAGTAA  1050 
 
 
B. 
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C. 
 
 
Figure 3.6: Nucleotide sequence analysis of the constructed Vpu::GFP plasmid. A) 
Nucleotide sequencing confirmed the correct cloning of the Vphu fragment into the 
pcDNATM 6.2/C-EmGFP TOPO vector in frame with the EmGFP. The vpu portion is 
shown in blue, while GFP is indicated in green. The underlined codons represent the 
serine residues that were replaced with alanine residues (pink) in both the single and 
double phosphorylation mutants. B) Nucleotide sequencing chromatogram indicating a 
single mutation of Ser52 to Ala52 for Vpu-SM. C) Nucleotide sequencing chromatogram 
indicating a double mutation of both Ser52 and Ser56 to Ala52 and Ala56. 
 
The pVpu::GFP plasmid was used to successfully transfect HEK 293T and U937 
cell lines using Lipofectamine and electroporation for protein expression and cell-
based assays, respectively, after optimal transfection conditions had been 
established. Expression of the Vpu::GFP fusion protein was confirmed by the 
presence of GFP using fluorescence microscopy (Figure 3.7) as well as by SDS-
PAGE and Western blotting (Figure 3.8; expected size of approximately 36 kDa). 
Approximately 1 ml of partially purified protein was obtained at a concentration of 
0.979 mg/ml from a 6-well microtiter plate with 0.25 X 106 cells /ml in each well, 2 
ml per well. The cells from each well were combined before isolation and 
purification, making a total of 3 X 106 HEK 293T cells used to isolate Vpu::GFP 
and the soluble supernatant fraction was used in subsequent in vitro assays. This 
was calculated using the Beer-Lambert equation and the extinction coefficient of 
Vpu::GFP (1.042 g-1.dm3.cm-1) after the absorbance had been measured by 
Nanodrop spectrophotometry (Figure 3.9).  
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Figure 3.7: Micrographs taken of control and transfected HEK 293T and U937 cells 
at 48 hours post-transfection. Images were taken of A) control HEK 293T cells and B) 
Vpu::GFP transfected HEK 293T adherent cells using the Floid fluorescent imager at 20X 
magnification. An Olympus CKX41 fluorescent microscope was used to take images of C) 
U937 suspension cells transfected with a control pMax GFP vector and D) Vpu::GFP-
transfected U937 cells at 10X magnification.  
 
 
Figure 3.8: Analysis and Western blot showing expression of the Vpu::GFP fusion 
protein in HEK 293T cells at approximately 36 kDa. The Chemidoc
TM
 MP System was 
used to obtain images of the A) SDS-PAGE and Western blots and indicated the 
presence of the Vpu::GFP fusion protein in the solubilized sample (red arrow) using B) 
anti-Vpu antibodies, C) anti-GFP antibodies and D) the phosphorylation of the fusion 
protein. Molecular weight (Bio-Rad, USA) in kDa is indicated on the left. 
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Figure 3.9: The absorbance spectrum of the Vpu::GFP fusion protein. The calculated 
concentration of the purified recombinant protein in the supernatant fraction was 0.979 
mg/ml using Nanodrop spectrophotometry and the extinction coefficient of Vpu::GFP of 
1.042 g
-1
.dm
3
.cm
-1
. 
 
3.3 Binding interaction of Vpu with CD4 and CD74 
The partially purified Vpu::GFP fusion protein was evaluated for its interaction 
with CD4, CD74 and a control peptide CLIP using in vitro assays, as detailed in 
the subsequent sections. Overlapping peptides for both Vpu and CD74 were also 
evaluated for binding in the same way. All ELISA results are summarized in 
Addendum B, Table A.1. Results shown below indicate these detailed data for 
the binding interactions. 
 
3.3.1 Confirmation of Vpu binding CD4 and CD74 
The interaction between recombinant Vpu::GFP and CD4 or CD74 peptides was 
investigated in vitro using ELISAs. The protocol used for this assay was adapted 
from Hussain et al. (2008) and optimized for this study. Although the binding 
between Vpu and CD4 had previously been established (Willey et al., 1994; 
Tiganos et al., 1997), this was investigated through ELISA to confirm the 
interaction between these two proteins for this study. Using an anti-CD4 antibody 
that targets the CD4 cytoplasmic domain, it was indirectly observed that 
Vpu::GFP does indeed bind the CD4 peptide (Figure 3.10). Coating buffer (CB), 
Vpu::GFP or CD74 alone did not elicit a response. However, when the CD4 
peptide was added to the coated Vpu::GFP, the responses obtained were 
equivalent to that of the CD4 peptide coated and incubated directly with the 
antibody without the addition of any other peptides. Results also confirm that the 
recombinant Vpu::GFP used in these assays was of sufficient purity since the 
background absorbance was low. 
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Figure 3.10: Interactions between full length recombinant Vpu::GFP and CD74 or 
CD4 peptides with anti-CD4 antibody. The interaction between the cytoplasmic 
domains of CD74 and CD4 peptides (500 ng each) with the full length Vpu::GFP protein 
(400 ng) using an anti-CD4 antibody directed against the CD4 cytoplasmic region is 
shown. The responses indicate binding between CD4 and Vpu. Values for each peptide 
are mean absorbance ± standard deviation. CB – coating buffer. 
 
The binding of an anti-CD74 antibody to the Vpu/CD74 complex was tested in the 
same manner as that for anti-CD4, in which either Vpu::GFP or CD74 peptide 
was coated onto an ELISA plate and then incubated with the opposite protein 
before the addition of anti-CD74 antibody (Figure 3.11). This assay indicated that 
Vpu and CD74 do bind as previously reported (Hussain et al., 2008), as all wells 
that contained CD74 resulted in a high signal. This response was specific as the 
control samples had significantly lower responses (p < 0.0500) and CD74 alone 
yielded similar responses to Vpu incubated with CD74 (p = 0.9336).  
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Figure 3.11: Interactions between full length recombinant Vpu::GFP and CD74 or 
CD4 peptides with anti-CD74 antibody. The interaction between the cytoplasmic 
domains of CD74 and CD4 peptides (500 ng each) with the full length Vpu::GFP protein 
(400 ng) using an anti-CD74 antibody directed against the CD74 cytoplasmic region is 
shown. The responses obtained correlate the binding between CD74 and Vpu. Values for 
each peptide are mean absorbance ± standard deviation. CB – coating buffer. 
 
3.3.2 CD74 binds to an immunodominant domain on Vpu 
The binding interaction between Vpu and CD74 was further investigated using an 
anti-Vpu antibody as well as an anti-GFP antibody (Figure 3.12), where samples 
incubated with anti-Vpu are shown in blue and samples incubated with anti-GFP 
are shown in green. A control peptide, CLIP, is also indicated with no binding to 
Vpu::GFP. It can be seen that regardless of whether CD74 peptide is coated and 
incubated with Vpu::GFP, or if CD74 peptide is incubated with the coated 
Vpu::GFP, the response is significantly lower than that of Vpu::GFP alone using 
the anti-Vpu antibody (p = 0.0000 and 0.0002 for CD74 peptide coating and 
Vpu::GFP coating respectively). However, when using the anti-GFP antibody, the 
addition of CD74 peptide to the coated Vpu::GFP does not reduce the response. 
In addition to this, when CD74 peptide is coated and incubated with Vpu::GFP 
and followed by anti-GFP, a higher response is obtained, indicating the presence 
of the Vpu::GFP fusion protein bound to the coated CD74 peptide. This indicates 
that the CD74 peptide binds to an epitope in the immunodominant domain on 
Vpu. The use of the anti-GFP antibody eliminated the reduction in response as 
this antibody would bind to the GFP tag on the Vpu::GFP fusion protein. 
Therefore, the binding of anti-GFP was not hindered/affected by the presence of 
the CD74 peptide bound to the immunodominant domain of Vpu. 
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Figure 3.12: Interactions between Vpu::GFP and CD74 or CLIP peptides. The 
interactions between the full length cytoplasmic domains of CD74 and the CLIP control 
peptides with the full length Vpu::GFP protein using the subtype B anti-Vpu antibody 
(blue) and the anti-GFP antibody (green) are indicated respectively. Values for each 
peptide are mean absorbance ± standard deviation. Asterices are indicative of significant 
differences in response. 
 
In order to determine the effectiveness of the CD74 peptide in preventing the 
binding of the anti-Vpu antibody to Vpu::GFP, a dose response assay was 
conducted in which increasing concentrations of CD74 peptide (100, 250, 500, 
1000, 5000 and 10 000 ng) were incubated with 400 ng of coated Vpu::GFP 
(Figure 3.13). When plotting the response against the log of the CD74 
concentration, an IC50 of 888.67 ± 130.08 nM was obtained. This indicates that 
the CD74 peptide competes with anti-Vpu antibody for binding to the 
immunodominant region on the cytoplasmic domain of Vpu.  
 
 
Figure 3.13: Fitted dose response curve for the Vpu/CD74 interaction. Subtype B 
anti-Vpu antibody was effectively inhibited by the CD74 peptide from binding to Vpu::GFP 
with an IC50 of 888.67 ± 130.08 nM. Values for the CD74 peptide are mean absorbance ± 
standard deviation. 
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3.3.3 CD4 and CD74 compete for binding to Vpu 
As both CD4 and CD74 interact with Vpu via the cytoplasmic domains, these 
peptides may compete for binding to Vpu. Results from a competitive binding 
assay using the 29-mer and 30-mer cytoplasmic peptides of CD4 and CD74, 
respectively with the full length Vpu::GFP fusion protein are shown in Figure 3.14. 
The CD4 peptide was coated onto a plate and then incubated with Vpu::GFP that 
had been pre-incubated with increasing concentrations of the CD74 peptide (0, 
250, 500, 1000, 5000 and 10 000 ng). At 0 ng of CD74 peptide, Vpu::GFP was 
able to bind the CD4 peptide, yielding a high response. However, as the 
concentration of the CD74 peptide increased, the response decreased, indicating 
that the ability of Vpu::GFP to bind to CD4 was inhibited. The pre-incubation of 
Vpu::GFP with the CD74 peptide reduced the binding of Vpu to the CD4 peptide 
2-fold at a concentration of 250ng. This data suggests that the tested CD4 and 
CD74 peptides bind to the cytoplasmic domain of Vpu within closely related 
regions, and compete for binding to Vpu.  
 
 
Figure 3.14: Competitive binding study between CD4 and CD74 peptides to 
Vpu::GFP. The pre-incubation of Vpu::GFP with increasing concentrations of the 
cytoplasmic CD74 peptide before interaction with the coated CD4 peptide yielded a 
decrease in response which correlates to a decrease in the binding of Vpu to CD4. This 
data indicates that CD4 and CD74 bind to Vpu within a closely related region within the 
cytoplasmic domain.  
 
3.3.4 Binding site delineation 
ELISA data presented previously (section 3.3.2) suggested that CD74 binds to 
the immunodominant region on Vpu and thus prevents the binding of the anti-Vpu 
antibody. In order to specifically delineate the binding site, the interaction 
between overlapping peptide sets of both Vpu and CD74 was investigated in vitro 
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using ELISAs. Initially, 400 ng per well of the overlapping Vpu peptides were 
tested with subtype B (Figure 3.15A) and subtype C (Figure  3.15B) anti-Vpu 
antiserum, respectively, in order to obtain baseline responses for each of these 
overlapping peptides with the respective antibodies. For each antibody subtype, 
two peptides from the overlapping peptide set were recognised and bound, which 
may indicate the immunodominant regions on the Vpu cytoplasmic domain. For 
the subtype B antibody, these were peptides 10 and 13 with the amino acid 
sequences of ILRQRKIDRLIDRIR and RIRERAEDSGNESEG, respectively. 
When using the subtype C anti-Vpu antibody, the two reactive peptides included 
numbers 10 and 11 with the amino acid sequence of peptide 11 being 
RKIDRLIDRIRERAE. Peptide 13 was not recognized and bound by the subtype 
C antibody, while peptide 11 was not bound by the subtype B antibody. On closer 
inspection, the subtype B antibody yielded a 1.7 fold higher response for peptide 
10 compared to peptide 13 while the subtype C antibody yielded a 2.06 fold 
higher response for peptide 11 compared to peptide 10. 
  
 
Figure 3.15: Testing of Vpu overlapping peptides (NIH) with A) a subtype B anti-Vpu 
antiserum (NIH cat #969) and B) a subtype C anti-Vpu antiserum (NIH cat #11942). 
In this data set, only two peptides bind the antibodies – numbers 10 and 13 with 
sequences of ILRQRKIDRLIDRIR and RIRERAEDSGNESEG respectively for subtype B 
and number 10 and 11 with sequences of ILRQRKIDRLIDRIR and RKIDRLIDRIRERAE 
respectively for subtype C. Values for each peptide are mean absorbance ± standard 
deviation. 
 
Following this, the Vpu overlapping peptides were tested against two overlapping 
peptide sets of the CD74 cytoplasmic domain in which the two responsive Vpu 
peptides described in Figure 3.15 were coated and then incubated with the CD74 
peptide sets (Figure 3.16). 
10 
13 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
M
Q
SL
Q
IL
A
I
Q
IL
A
IV
A
LV
IV
A
LV
V
A
A
I
V
V
A
A
IIA
IV
IIA
IV
V
W
TI
V
V
W
TI
V
FI
E
V
V
W
TI
V
FI
EY
R
KI
LR
IV
FI
EY
R
K
IL
R
Q
R
K
I
EY
R
K
IL
R
Q
R
K
ID
R
LI
IL
R
Q
R
K
ID
R
LI
D
R
IR
R
KI
D
R
LI
D
R
IR
ER
A
E
R
LI
D
R
IR
ER
A
ED
SG
N
R
IR
ER
A
ED
SG
N
ES
EG
R
A
ED
SG
N
ES
EG
D
Q
EE
SG
N
ES
EG
D
Q
EE
LS
A
L
SE
G
D
Q
EE
LS
A
LV
EM
G
Q
EE
LS
A
LV
EM
G
H
H
A
P
SA
LV
EM
G
H
H
A
PW
D
V
D
EM
G
H
H
A
P
W
D
V
D
D
L
A
b
so
rb
an
ce
 (
A
6
5
0)
 
10 
11 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
M
Q
SL
Q
IL
A
I
Q
IL
A
IV
A
LV
IV
A
LV
V
A
A
I
V
V
A
A
IIA
IV
IIA
IV
V
W
TI
V
V
W
TI
V
FI
E
V
V
W
TI
V
FI
EY
R
KI
LR
IV
FI
EY
R
K
IL
R
Q
R
K
I
EY
R
K
IL
R
Q
R
K
ID
R
LI
IL
R
Q
R
K
ID
R
LI
D
R
IR
R
KI
D
R
LI
D
R
IR
ER
A
E
R
LI
D
R
IR
ER
A
ED
SG
N
R
IR
ER
A
ED
SG
N
ES
EG
R
A
ED
SG
N
ES
EG
D
Q
EE
SG
N
ES
EG
D
Q
EE
LS
A
L
SE
G
D
Q
EE
LS
A
LV
EM
G
Q
EE
LS
A
LV
EM
G
H
H
A
P
SA
LV
EM
G
H
H
A
PW
D
V
D
EM
G
H
H
A
P
W
D
V
D
D
L
A
b
so
rb
an
ce
 (
A
6
5
0)
 A B 
 59 
 
When using the subtype B anti-Vpu antibody (Figure 3.16A), the addition of the 
CD74 10-mer peptide set to Vpu peptide 10 yielded no significant difference (p > 
0.0500) in the response, suggesting that either these CD74 peptides do not bind 
to the ILRQRKIDRLIDRIR sequence or that the peptides are too small to have 
any influence over the binding of the antibody. However, when examining the 
response of Vpu peptide 13, the addition of CD74_10.2 and CD74_10.3 yield a 
significant response (p = 0.0098 and p = 0.0178, respectively) while the 
remaining CD74 peptides did not. This suggests that the binding site may be 
between the Vpu sequence of RIRERAEDSGNESEG and the CD74 overlapping 
sequences of SRSCREDQKP and EDQKPVMDDQ, both of which contain the 
residues EDQKP. 
 
 
Figure 3.16: Interaction of coated Vpu overlapping peptides 10 and 13 with CD74 
overlapping peptides. A) Overlapping 10-mer CD74 peptides and B) overlapping 15-
mer CD74 peptides were used followed by the subtype B anti-Vpu antibody. Only data 
from the two responsive peptides from the Vpu peptide set are shown. Values for each 
peptide are shown as the mean absorbance ± standard deviation. BLR – baseline 
response. Asterices are indicative of significant differences in response. 
 
The incubation of the Vpu peptides with a 15-mer overlapping peptide set of the 
cytoplasmic domain of CD74 yielded a different response to that of the 10-mer 
CD74 peptide set when using the subtype B anti-Vpu antibody (Figure 3.16B). A 
significant increase is observed in the responses of Vpu peptide 10 with the 
different CD74 15-mer peptides (p < 0.0500), as seen in Figure 3.16B in 
comparison to the baseline responses in Figure 3.15. This indicates a possibility 
of no binding between the CD74 15-mer peptide and Vpu peptide 10, and this 
particular increase in response may be due to non-specific binding. On closer 
inspection of the interaction between the CD74 15-mer peptides and Vpu peptide 
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13, the response of this Vpu peptide is almost completely abolished in the 
presence of all four of the 15-mer CD74 peptides (p < 0.0500). The reduction in 
this response may be caused by the blocking of the antibody binding site by the 
CD74 peptides. The differences in response obtained between the two different 
CD74 peptide sets suggests that the size of the peptides tested plays a role in 
this interaction, described in more detail in section 3.3.5 below. 
 
In order to determine if the abovementioned binding site between CD74 and Vpu 
is specific, a second anti-Vpu antibody was used that recognizes a different 
immunodominant domain within the Vpu cytoplasmic region. Initially, the 
overlapping Vpu peptide set was tested using this antibody to determine which 
peptides were responsive. It was found that the last two peptides, peptides 18 
and 19, were the responsive peptides with the sequences of 
SALVEMGHHAPWDVD and EMGHHAPWDVDDL, respectively. These two 
responsive peptides were then incubated with the two sets of CD74 overlapping 
peptides (Figure 3.17) but neither the 10-mer (Figure 3.17A) nor the 15-mer 
(Figure 3.17B) CD74 peptides were found to bind to these particular Vpu 
peptides as there was no significant difference in response between the Vpu 
peptides and those incubated with the CD74 peptides (p > 0.0500), which 
validates the previously mentioned binding site and indicates that the proposed 
binding site is specific between Vpu and CD74.  
 
 
Figure 3.17: Interaction of coated Vpu overlapping peptides 18 and 19 with CD74 
overlapping peptides. A) Overlapping 10-mer CD74 peptides were used and B) 
overlapping 15-mer CD74 peptides were used followed by an anti-Vpu antibody that 
recognizes a different epitope to that described in Figure 3.16. Values for each peptide 
are shown as the mean absorbance ± standard deviation. BLR – baseline response. 
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When this same assay was repeated using the cytoplasmic domain of CD4 
(Figure 3.18), it was seen that the addition of CD4 significantly reduced the 
response of the two Vpu peptides (p = 0.0000 and 0.0006 for peptides 18 and 19, 
respectively). This concurs with the CD4 binding sites on Vpu found by Schneider 
et al. (1990), Margottin et al. (1996) and Tiganos et al. (1997). Notably, the 
decrease in response is more pronounced with peptide 19 than peptide 18, 
suggesting that these residues may be more important in the binding of CD4 and 
Vpu. 
 
 
Figure 3.18: Interaction of coated Vpu overlapping peptides 18 and 19 with CD4 
cytoplasmic peptide. Responses both with and without the CD4 cytoplasmic domain are 
indicated after using an anti-Vpu antibody that recognizes a different epitope to that of 
Figure 3.16. CD4 reduces the responses of peptide 19 by 2.1 fold and peptide 18 by 1.3 
fold. Values for each peptide are shown as the mean absorbance ± standard deviation. 
Asterices are indicative of significant differences in response. 
 
Following this, 400 ng of the responsive Vpu peptides from the overlapping 
peptide set was then tested for binding against 500 ng of the CLIP control 
peptide and 500 ng of the cytoplasmic domains of both CD74 and CD4 (Figure 
3.19). When using the subtype B antibody (Figure 3.19A), the addition of the 
CLIP peptide did not reduce the response in comparison to the baseline 
responses (see Figure 3.15A), while the CD4 cytoplasmic domain peptide 
enhanced the response of peptides 10 and 13 in comparison to the baseline. 
This enhanced response was more significant with Vpu peptide 10 than peptide 
13 (p = 0.0112 and 0.3722, respectively). In contrast to CD4, the addition of the 
CD74 cytoplasmic domain peptide resulted in a significant decrease in the 
response (p = 0.0012 and 0.0112 for peptide 10 and 13, respectively), while there 
was no significant difference after CLIP incubation (p = 0.2500 and 0.8742, 
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respectively). When repeating the interaction of the overlapping Vpu peptides 
with CLIP, CD74 and CD4 using the subtype C antibody (Figure 3.19B), a similar 
pattern was seen as with the subtype B antibody in which only the CD74 
cytoplasmic domain induced a reduction in the response. However in this case, 
peptides 10 and 11 were tested, as previously mentioned. CD4 once again 
significantly enhanced the response obtained (p = 0.0008 and 0.0236 for 
peptides 10 and 11, respectively) while CD74, as with the subtype B antibody, 
reduced the response obtained significantly in comparison to the baseline 
response (p = 0.0022 and 0.0000 for peptides 10 and 11, respectively), while 
there was no significant difference after CLIP incubation (p = 0.2642 and 0.0906 
for peptides 10 and 11, respectively).  
 
 
Figure 3.19: CD74 reduces antibody binding to Vpu peptides while CD4 enhances 
antibody binding. The interaction between the coated Vpu overlapping peptides with the 
full length cytoplasmic domains of CD74, CD4 and the CLIP peptide using A) the subtype 
B anti-Vpu antibody and B) the subtype C anti-Vpu antibody. Only the two responsive 
Vpu peptides (10 and 11) are shown. Values for each peptide are mean absorbance ± 
standard deviation. BLR – baseline response. Asterices are indicative of significant 
differences in response. 
 
As an increase in response upon the addition of the CD4 cytoplasmic peptide 
was unexpected, the presence of CD4 bound to the Vpu peptides was validated 
by repeating the assay using an antibody that recognizes the C-terminal domain 
of CD4 (Figure 3.20). The Vpu peptides alone did not yield a response with this 
antibody, while the addition of the CD4 cytoplasmic peptide generated a 
significantly increased response (p < 0.0500). This confirmed the presence of 
CD4, bound to the selected Vpu peptides.  
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Figure 3.20: CD4 binds to the Vpu responsive peptides. The interaction between the 
coated Vpu overlapping peptides with the full length cytoplasmic domain of CD4 using an 
anti-CD4 antibody that recognizes the C-terminus of CD4. Only the responsive Vpu 
peptides (10 in blue, 11 in red and 13 in green) are shown. Values for each peptide are 
mean absorbance ± standard deviation. Asterices are indicative of significant differences 
in response. 
 
3.3.5 Peptide size plays a role in antibody inhibition 
Once the interaction between the Vpu and both CD74 overlapping peptide sets 
had been established, both of the CD74 overlapping peptide sets were tested 
using the full length purified Vpu::GFP fusion protein (Figure 3.21). With both 
CD74 peptide sets, the responses obtained were high with the exception of the 
CD74_15.1 peptide which was slightly lower (not significant) than its 
counterparts.  
 
 
Figure 3.21: Individual peptides are unable to prevent antibody binding. The 
interaction between the full length Vpu::GFP fusion protein with A) the CD74 10-mer 
overlapping peptide set both individually (red) and in combinations (green) and B) the 
CD74 15-mer overlapping peptide set. Values for each peptide are shown as the mean 
absorbance ± standard deviation. Asterices are indicative of significant differences in 
response.  
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As previously mentioned, it was considered that the size of the peptides may be 
an influencing factor in the ability of CD74 to prevent the binding of the anti-Vpu 
antibody. In order to explore this concept, combinations of the CD74 10-mer 
peptides were incubated with the Vpu::GFP fusion protein (Figure 3.21A, green). 
It was noted that these combinations of the 10-mer CD74 peptides were able to 
prevent the binding of the anti-Vpu antibody to the Vpu::GFP fusion protein and 
reduce the response significantly (p < 0.0500 for all combinations as compared to 
all individual peptides) in comparison to individual peptides. While a single, 
individual CD74 peptide was unable to prevent antibody binding (Figure 3.21A 
red), a combination of only two of these peptides was enough to reduce the 
response, indicating that the size of the CD74 overlapping peptides plays a role 
in preventing the binding of anti-Vpu. 
  
3.4 CD4, CD74 and MHCII are downregulated in the presence of 
Vpu 
The downstream consequence of the Vpu/CD4 interaction is the targeting of CD4 
for proteasomal degradation (Fujita et al., 1997; Schubert et al., 1998). Taking 
into consideration the structural similarities between CD4 and CD74 as indicated 
in section 3.1, and the competition between these two host proteins for binding to 
Vpu (Figure 3.14), it is possible that the interaction between CD74 and Vpu will 
also lead to the downregulation and/or degradation of CD74. Once an optimal 
protocol for CD74 immunoprecipitation had been established, the transfection of 
U937 cells with pVpu::GFP resulted in the complete reduction of total cellular 
CD74 levels (Figure 3.22) seen after immunoprecipitation from whole cell lysate, 
while both untransfected cells and cells transfected with a control GFP vector 
(pMax) were still found to have high levels of CD74 after immunoprecipitation. 
 
 
Figure 3.22: Total CD74 levels are downregulated by Vpu::GFP. Western blot probing 
for CD74 after immunoprecipitation with mouse anti-CD74 antibody from untransfected 
cells, pMax control transfected cells and Vpu::GFP transfected cells. The presence of 
CD74 is indicated in both control sets, but a complete absence of CD74 in the presence 
of Vpu::GFP. CD74 appears as a doublet around 15 kDa. The secondary antibody used 
was HRP-labelled rabbit anti-mouse IgG. 
15 kDa 
Untransfected pMax Vpu::GFP 
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Next, the downregulation of native CD4, MHCII and CD74 was investigated via 
flow cytometry. The protocol for cell treatment, staining and analysis was 
optimized prior to the measurement of samples. The Vpu-mediated 
downregulation and degradation of CD4 has been previously reported (Fujita et 
al., 1997; Schubert et al., 1998; Hill et al., 2010; Magadan et al., 2010). This 
finding was corroborated within this study using flow cytometry in which mock-
transfected U937 cells were found to have high/normal levels of CD4 and those 
cells transfected with pVpu::GFP had significantly lower CD4 levels (p = 0.0000; 
Figure 3.23). This was investigated at 24 hours only for confirmatory purposes as 
the downregulation of this protein by HIV-1 Vpu has already been reported, as 
previously mentioned. Total cellular CD4 levels were measured in U937 cells by 
permeabilization of the cells prior to staining with an anti-CD4 antibody. Statistical 
data for six replicates is indicated in Table 3.1. 
 
 
 
Figure 3.23: CD4 is downregulated by Vpu in U937 cells at 24 hours post-
transfection. Yellow fluorescence counts for total CD4 levels of mock-transfected cells 
(red) and Vpu-transfected cells (black) cells after 24 hours post-transfection and staining 
with a PE-labelled antibody. The cell count is indicated on the y-axis while CD4 levels are 
indicated on the x-axis. 
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Table 3.1: Average fluorescence counts (± SD) for total CD4 levels in U937 cells that 
were either mock-transfected or Vpu-transfected. Statistically significant differences are 
indicated by p values in bold red.  
  Average Standard 
Deviation 
p Value 
24 Hours Mock-transfected 155.53 25.42 0.0000 
Vpu-transfected 24.44 6.45 
 
 
As with CD4 described above, the downmodulation of MHCII in the presence of 
Vpu in U937 cells has already been reported (Hussain et al., 2008). This 
downregulation was confirmed within this study via flow cytometry at 24 hours but 
not at 48 hours post transfection with pVpu::GFP. This trend was seen regardless 
of the prior treatment of the cells, i.e. no activation or activation with either PMA 
or IFN-γ. When control cells were left untreated prior to transfection (Figure 
3.24A), a significant decrease in total MHCII levels was seen at 24 hours post 
transfection in the presence of Vpu compared to mock-transfected cells (p = 
0.0156), but no significant decrease was seen at 48 hours post transfection (p = 
0.4470). This was also indicated with PMA-activation of cells prior to transfection 
(Figure 3.24B), with a significant decrease again at 24 hours (p = 0.0032) in the 
presence of Vpu and no significant decrease at 48 hours (p = 0.6184). Finally, 
IFN-γ-activation of cells prior to transfection (Figure 3.24C) yielded the same 
significant decrease in total MHCII levels at 24 hours with Vpu (p = 0.0004) and 
no decrease at 48 hours post transfection (p = 0.6630). At 48 hours post-
transfection, Vpu-transfected cells for all three treatment types yielded two 
populations. These are most likely parent and daughter populations, with the 
daughter population expressing greater levels of MHCII as these cells were not 
expressing Vpu. A summary of the statistical data for six replicates of each 
condition is provided in Table 3.2. 
 
 67 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control  
24 hour 
Control  
48 hour 
PMA  
24 hour 
PMA  
48 hour 
Total MHCII Levels (GRN-HLog) 
Total MHCII Levels (GRN-HLog) 
C
o
u
n
t 
A 
B 
C
o
u
n
t Vpu 
Vpu 
Vpu 
Vpu 
Mock 
Mock 
Mock Mock 
 68 
 
 
 
Figure 3.24: Effect of Vpu on MHCII levels in A) control, B) PMA-treated and C) IFN-
γ-treated U937 cells at 24 hours but not 48 hours. Green fluorescence counts 
indicating MHCII levels for control, PMA-treated and IFN-γ-treated, mock-transfected cells 
(pink) and Vpu-transfected cells (grey) cells after 24 hours and 48 hours post-transfection 
and staining for GFP. The cell count is indicated on the y-axis while CD4 levels are 
indicated on the x-axis. 
 
Table 3.2: Average fluorescence counts (± SD) are indicated for total MHCII levels in 
U937 cells that were either mock-transfected or Vpu-transfected. Statistically significant 
differences are indicated by p values in bold red.  
  Average Standard 
Deviation 
p Value 
24 
hours 
Control Mock 558.46 166.70 0.0156 
Control Vpu 330.65 86.98 
    
PMA Mock 528.41 112.02 0.0032 
PMA Vpu 304.85 52.02 
    
IFN-γ Mock 440.29 40.16 0.0004 
IFN-γ Vpu 232.13 77.39 
     
48 
hours 
Control Mock 371.98 65.68 0.4470 
Control Vpu 431.96 158.10 
    
PMA Mock 377.87 52.74 0.6184 
PMA Vpu 355.63 90.67 
    
IFN-γ Mock 380.05 72.25 0.6630 
IFN-γ Vpu 351.73 141.75 
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The binding of CD74 and Vpu via their cytoplasmic domains as well as the 
similarities between CD4 and CD74 suggest that this human protein is 
downregulated and/or degraded in the presence of HIV-1 Vpu. This was 
indicated previously in Figure 3.22 and subsequently confirmed using flow 
cytometry. The three different sets of U937 cells - control, PMA-treated and IFN-
γ-treated – were either mock-transfected with no plasmid or transfected with 10 
µg of pVpu::GFP and analysed for total CD74 levels both at 24 hours and 48 
hours post transfection. When cells were left untreated prior to transfection 
(Figure 3.25A; control), a significant decrease in total CD74 levels was found at 
24 hours post transfection in the presence of Vpu compared to mock-transfected 
cells (p = 0.0270), as well as at 48 hours post transfection (p = 0.0062). However, 
after PMA-activation of cells prior to transfection (Figure 3.25B) and IFN-γ-
activation of cells prior to transfection (Figure 3.25C), no significant decrease in 
CD74 was seen at 24 hours post transfection (p = 0.1592 and 0.0990, 
respectively) but 48 hours post transfection yielded a significant decrease in total 
CD74 levels (p = 0.0236 and 0.0000, respectively). A summary of the statistical 
data for six replicates of each condition is indicated in Table 3.3 for CD74 levels. 
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Figure 3.25: Effect of Vpu on CD74 levels in A) control, B) PMA-treated and C) IFN-
γ-treated U937 cells. Yellow fluorescence counts indicating CD74 levels for control 
(pink), PMA-treated (blue) and IFN-γ-treated (purple) mock-transfected cells compared to 
Vpu-transfected cells (grey) cells after 24 hours and 48 hours post-transfection and 
staining with a PE-labelled antibody. The cell count is indicated on the y-axis while CD4 
levels are indicated on the x-axis. 
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Table 3.3: Average fluorescence counts (± SD) are indicated for total CD74 levels in 
U937 cells that were either mock-transfected or Vpu-transfected. Statistically significant 
differences are indicated by p values in bold red.  
    Average Standard 
Deviation 
p Value 
24 hour Control Mock 765.96 221.72 0.0270 
Control Vpu 443.47 210.27 
        
PMA Mock 665.81 232.01 0.1592 
PMA Vpu 413.90 328.58 
        
IFN-γ Mock 601.85 258.80 0.0990 
IFN-γ Vpu 375.97 147.35 
          
48 hour Control Mock 1109.68 247.12 0.0062 
Control Vpu 684.69 189.46 
        
PMA Mock 953.97 245.49 0.0236 
PMA Vpu 586.14 233.02 
        
IFN-γ Mock 875.17 109.85 0.0000 
IFN-γ Vpu 439.83 128.47 
 
As previously mentioned, Vpu requires two phosphorylated serine residues in 
order to recruit the E3 ligase complex and target CD4 for proteasomal 
degradation (Margottin et al., 1998; Nomaguchi et al., 2008; reviewed in Andrew 
and Strebel, 2010). In order to determine if CD74 may also be degraded via the 
proteasome, CD74 levels were measured in U937 cells after transfection with two 
Vpu phosphorylation mutants, pVpu-SM or pVpu-DM and analysed for total CD74 
levels both 24 hours and 48 hours post-transfection (Figure 3.26, Table 3.4). A 
significant decrease in total CD74 levels was seen at 24 hours post-transfection 
for both Vpu-SM and Vpu-DM compared to mock-transfected cells (p = 0.0088 
and 0.0120, respectively). At 48 hours post-transfection, a difference was seen 
between the Vpu-SM and Vpu-DM mutants. At this time point, Vpu-SM yielded no 
significant downregulation of CD74 compared to mock-transfected cells (p = 
0.3358), while Vpu-DM caused a significant downregulation of CD74 (p = 
0.0002). 
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Figure 3.26: CD74 is downregulated by A) Vpu-SM in U937 cells at 24 hours and is 
downregulated by B) Vpu-DM at both 24 and 48 hours. Yellow fluorescence counts 
indicating CD74 levels for mock-transfected cells (Vpu-SM – red; Vpu-DM – blue) and 
pVpu-SM/DM-transfected cells (grey) cells after 24 hours and 48 hours post-transfection 
and staining with a PE-labelled antibody. The cell count is indicated on the y-axis while 
CD4 levels are indicated on the x-axis. 
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Table 3.4: Average fluorescence counts (± SD) are indicated for total CD74 levels in 
U937 cells that were either mock-transfected or Vpu-transfected with the Vpu single (SM) 
and double (DM) phosphorylation mutants. Statistically significant differences are 
indicated by p values in bold red.  
    Average Standard 
Deviation 
p Value 
24 hour Mock 765.96 221.72 0.0088 
Vpu-SM 400.95 98.12 
        
Mock 765.96 221.72 0.0120 
Vpu-DM 422.83 131.63 
          
48 hour Mock 1109.68 247.12 0.3358 
Vpu-SM 1281.75 312.53 
        
Mock 1109.68 247.12 0.0002 
Vpu-DM 269.56 65.55 
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CHAPTER FOUR: DISCUSSION 
 
The HIV-1 Vpu accessory protein is actively involved in the establishment of 
infective persistence as it is able to connect viral and host cellular proteins to 
cellular pathways, as well as regulate these pathways through protein-protein 
interactions in order to promote viral replication (Willey et al., 1992a). As 
previously mentioned, individuals infected with HIV (or SIV) isolates that do not 
express a functional Vpu protein exhibit less severe disease outcomes 
(Leligdowicz and Rowland-Jones, 2008). Within this study, the residues involved 
in the Vpu/CD74 interaction are described for the first time, and it is 
demonstrated that Vpu targets intracellular CD74 for downregulation, which 
occurs at a cellular location where other viral proteins possibly do not, i.e. the ER. 
Finally, it was found that Vpu does not target CD74 for proteasomal degradation 
involving the phosphorylated serine residues and the recruitment of β-TrCP. 
 
4.1 CD4 and CD74 are structurally similar 
Similarities between CD4 and CD74 highlighted in section 1.6 implied that these 
proteins have the same fate after interacting with HIV-1 Vpu. The in silico 
comparisons and modelling conducted in this study also indicated structural 
similarities between the cytoplasmic domains of these two proteins. Both of these 
proteins have a combination of unstructured regions and α-helices in their 
cytoplasmic domains, with the hydrophobic residues clustered to one side of the 
helix (Figures 3.1 and 3.2). Furthermore, the hydropathy was calculated using the 
Kyte and Doolittle hydropathy scale (Kyte and Doolittle, 1982). As expected, the 
average hydropathy of the CD4 and CD74 cytoplasmic domains calculated using 
this scale indicate that these peptides are largely hydrophilic which is indicative of 
the cytoplasmic environment in which they are found.  
 
The structures of the transmembrane and cytoplasmic domains of a cysteine-free 
CD4 mutant have been determined by NMR in DPC micelles (Wittlich et al., 
2010). Of particular interest to this study is the CD4 cytoplasmic domain which 
contains a single α-helix consisting of 10 residues (403 to 413), with the 
remaining sections being mostly unstructured (Wittlich et al., 2010). To date the 
only structures for CD74 that have been reported and are available on the PDB 
include the CLIP fragment, the trimeric ectodomain as well as the p41 fragment 
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(Jasanoff et al., 1998; Guncar et al., 1999; Schlundt et al., 2012). While the 
structure of the CD74 cytoplasmic domain has been determined in aqueous 
solution using NMR (Motta et al., 1995), this has not been deposited on the PDB 
and no crystal structure of the N-terminal cytoplasmic domain has been obtained 
as yet. Therefore no co-ordinates were available for use within this study. The 
primary sequence was used to create the CD74 cytoplasmic domain model. The 
NMR analysis of the CD74 cytoplasmic domain indicated an α-helix from Gln4 to 
Leu14 (Motta et al., 1995) of the shorter p33 CD74 isoform. However, the longer 
p35 isoform was used to predict the models as shown in Figures 3.2 and 3.5A. 
The p35 isoform has additional residues at the N-terminus compared to the p33 
isoform (Warmerdam et al., 1996) and this may cause a shift of the position of the 
α-helix from Gln4-Leu14 to Gln13-Leu23. This largely overlaps with the predicted 
α-helix as shown in Figures 3.2 and 3.5, which consist of the residues Met17-
Asn26. It is also possible that the prediction of the α-helix based on primary 
sequence alone would introduce some inaccuracies, as the average accuracy of 
methods that are used to predict protein secondary structure from the primary 
sequence is reported to be 80 % (King and Sternberg, 1996; Rost, 2001; Li et al., 
2014).  
 
Although primary sequence alignment indicated nominal identity and 
approximately half similarity between the CD4 and CD74 cytoplasmic domains 
(Figure 3.4), the modelling of the CD74 cytoplasmic domain onto a template of 
the CD4 cytoplasmic peptide with the exclusion of the transmembrane portion of 
CD4 (Figure 3.5A) indicated that from a structural standpoint, these regions are 
similar. A Ramachandran plot indicated that none of the modelled residues were 
found to be conformationally constrained (Figure 3.5B) suggesting that the Φ and 
Ψ angles of the residues in this model are indeed possible. It has previously been 
shown that the region spanning residues 402 to 420 within the CD4 cytoplasmic 
domain is necessary for the binding to Vpu and the Vpu-mediated degradation of 
CD4 (Chen et al., 1993; Bour et al., 1995). This region contains an α-helix 
indicated in Figures 3.1 and 3.5A. In view of this and taking into account that 
CD74 may also be downregulated and degraded through Vpu binding, the 
predicted α-helix of the CD74 cytoplasmic domain was aligned to an α-helix of 
the CD4 cytoplasmic domain. The aligned helices were shown to have a greater 
degree of similarity than that of the model in which the disordered/unstructured 
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regions were included in the alignment (Figure 3.5A compared to 3.5C). The 
disordered/unstructured regions would be more flexible than the structured 
regions, leading to an increased RMSD and may lead to an inaccuracy in terms 
of assessing either the similarity or dissimilarity between these proteins. The 
close similarity in the Vpu-binding site of CD4 (Chen et al., 1993; Tiganos et al., 
1997) to an α-helix in CD74 suggests that the CD74 α-helix may also be 
important for Vpu binding, as the α-helices may provide an interface for the 
protein-protein interaction. Such structural similarities between CD4 and CD74 
lends to the notion that the binding of Vpu to CD74 yields similar downstream 
consequences to that of CD4, such as the degradation of the host protein. 
 
4.2 CD4 and CD74 bind to different sequences within a closely 
related region on Vpu 
Both CD4 and CD74 are known to interact with Vpu via their cytoplasmic 
domains. This has been indicated in previous reports (Willey et al., 1994; Tiganos 
et al., 1997; Hussain et al., 2008) as well as within this study (Figures 3.10 and 
3.11). The structural similarity between these two host proteins suggests that 
they bind to Vpu within a closely related region. Previous reports found that 40 % 
of a group of individuals in the early stages of HIV infection had antibodies that 
recognized an 18-residue peptide in the cytoplasmic domain of Vpu, with the 
sequence VEMGVEMGHHAPWDVDDL. This suggests that this region of Vpu 
represents an immunodominant domain (Schneider et al., 1990). Following this, 
Bour et al. (1995) were unable to immunoprecipitate Vpu/CD4 complexes with 
the use of Vpu antisera demonstrating that the binding of CD4 to this particular 
region of Vpu prevents the binding of the Vpu antibody. It is then possible that 
this is the specific region associated with CD4 binding. An analogous finding to 
this is shown in Figure 3.12 in which the binding of the CD74 cytoplasmic peptide 
to a Vpu::GFP fusion protein significantly reduced the response, and effectively 
prevented the binding of the anti-Vpu antibody with an IC50 of 262.01 nM (Figure 
3.13), but was unable to reduce the response when using an anti-GFP antibody. 
This finding further indicates a similarity between the cytoplasmic domains of 
CD4 and CD74, as both CD4 and CD74 are able to prevent the binding of anti-
Vpu antibodies to Vpu.  
 
In addition to the sequence mentioned above (Schneider et al., 1990), it was 
found that residues 28-47 (IEYRKILRQRKIDRLIDRIR) and 76-81 (WDVDDL) in 
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the cytoplasmic domain of Vpu are needed in order to bind CD4 (Margottin et al., 
1996). Furthermore, the binding of an antibody directed against a Vpu 
cytoplasmic peptide with the sequence HAPWDVDDL was masked through the 
binding of CD4 to Vpu (Tiganos et al., 1997). In addition to these binding sites, 
two conserved residues, namely Leu63 and Val68 were found to be vital for the 
Vpu-mediated degradation of CD4 (Hill et al., 2010). These two residues lie within 
the second α-helix in the Vpu cytoplasmic domain (reviewed in Andrew and 
Strebel, 2010). Finally, CSP analysis indicated that residues in both Vpu 
cytoplasmic α-helices are involved in binding CD4 (Singh et al., 2012), which 
corroborates the finding by Margottin et al. (1996).  
 
Analysis of a Vpu overlapping peptide set indicated only two responsive peptides 
with both subtype B as well as subtype C anti-Vpu antibodies (Figure 3.15 A and 
B, respectively), suggesting that these peptides contain the immunodominant or 
antigenic regions for these particular antibodies. The use of an overlapping 
peptide set of the CD74 cytoplasmic domain in combination with the overlapping 
Vpu peptide set indicated that the specific CD74 binding site corresponds to the 
Vpu peptide with the sequence RIRERAEDSGNESEG (Figure 3.16) which is a 
region that lies between the two abovementioned CD4 binding sites. This binding 
site contains a 12-residue conserved region within the cytoplasmic domain of Vpu 
namely, ERAEDSGNESEG (Chen et al., 1993) which forms part of the linker 
region. This region holds the two conserved phosphorylated serine residues that 
are required for the binding of β-TrCP and ultimately E3 ligase complex 
recruitment for proteasomal degradation (Margottin et al., 1998; Nomaguchi et 
al., 2008; reviewed in Andrew and Strebel, 2010). Further to this, the CD74 
cytoplasmic peptide did not bind to the second CD4-binding site at the C-
terminus of Vpu (Figure 3.17), while the CD4 cytoplasmic peptide was confirmed 
to bind to the Vpu C-terminal overlapping peptides (Figure 3.18), corroborating 
the abovementioned binding site. While it has been confirmed previously that the 
cytoplasmic domains are involved in the binding interaction between Vpu and 
CD74 (Hussain et al., 2008), delineation of the novel binding site has not been 
shown before. However, it must be noted that other potential CD74 binding sites 
could exist as the antigenic region that is recognized by this particular antibody 
restricts this particular binding site determination. In other words, the 
unresponsiveness of the other overlapping Vpu peptides to this particular 
 78 
 
antibody prevents the delineation of any other residues that are involved in CD74 
binding. Also, it should be considered that the secondary structure of each 
individual peptide may differ from the overall secondary structure of the native 
Vpu cytoplasmic domain as a whole and that the solubility of each individual 
overlapping peptide may also influence the data obtained.  
 
In addition to the differences in specific binding sites mentioned above, the 
cytoplasmic domains of CD74 and CD4 induced different responses with regard 
to binding the responsive Vpu peptides with both the subtype B and subtype C 
antibodies (Figure 3.19). With the subtype B anti-Vpu antibody, peptides 10 and 
13 were responsive while with the subtype C anti-Vpu antibody, peptides 10 and 
11 were responsive. This shift in responsive peptide may be due to the presence 
of an additional 2-5 amino acids at the N-terminus of subtype C Vpu compared to 
subtype B Vpu (Hussain et al., 2007). The addition of the CD74 cytoplasmic 
peptide yielded lower responses as the presence of this peptide prevented the 
binding of both antibodies by binding to the same antigenic sites. In contrast, the 
addition of the CD4 cytoplasmic peptide induced higher responses suggesting 
that the binding of CD4 to Vpu causes a conformational change in the Vpu 
peptides, making them more likely to bind the antibody. In agreement with the 
abovementioned findings that detailed the Vpu cytoplasmic residues that are 
involved in CD4 binding, there was only a significant difference in response with 
Vpu peptides 10 (ILRQRKIDRLIDRIR) and 11 (RKIDRLIDRIRERAE), but not with 
peptide 13 (RIRERAEDSGNESEG) with the addition of the CD4 cytoplasmic 
peptide. Despite this lack of difference in response with peptide 13, CD4 still does 
bind to this peptide (Figure 3.20). It is possible that CD4 only induces a difference 
in response with peptides 10 and 11 as these peptides are more important in the 
binding interaction between Vpu and CD4, and as already stated, the addition of 
CD4 may induce conformational changes in the Vpu peptides allowing for better 
binding of the antibodies. This is because in a natural setting, the conformational 
state of Vpu may be altered by the interaction with other proteins (Kukol and 
Arkin, 1999; Lemaitre et al., 2006; Wittlich et al., 2009; reviewed in Andrew and 
Strebel, 2010). The different responses seen with CD4 and CD74 binding (Figure 
3.19) would also suggest that these proteins do not bind to the same sequences 
within the Vpu cytoplasmic domain. It is interesting to note that although the 
specific binding sites mentioned above for CD4 and CD74 do indeed differ, both 
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CD4 and CD74 bind to these same three Vpu peptides. This indicates that, as 
with CD4, there is more than one binding site for CD74 within the Vpu 
cytoplasmic domain.  
 
Although the CD4 and CD74 cytoplasmic peptides were shown to compete with 
each other for binding to Vpu (Figure 3.14), the exact binding site sequences on 
Vpu for these two proteins do indeed differ (Figures 3.17 to 3.19). When CD74 is 
bound to Vpu, either the CD4 binding site may be masked or steric hindrance 
may prevent both host proteins from binding simultaneously. In other words, both 
CD4 and CD74 are known to interact with Vpu via the cytoplasmic domains of 
each protein, and while the binding sites for these proteins may overlap, they are 
distinct from each other in terms of primary Vpu sequence.  
 
Another factor that plays a role in the binding interactions is steric hindrance. 
While single 10- or 15-mer CD74 peptides were unable to inhibit the antibody 
from binding the full Vpu protein (Figure 3.21), combinations as few as two 
peptides were able to abrogate the response indicating that while not all residues 
are involved in the binding interaction, those residues that are involved may be 
blocked by larger peptides. This could also explain the steric hindrance between 
CD4 and CD74 (Figure 3.14) and indicates how these proteins are able to 
compete for binding to Vpu despite the differences in their binding sites.  
 
Overall, while there may be differences in the exact binding regions between CD4 
and CD74, there is enough similarity between these two host proteins and their 
interaction with HIV-1 Vpu to suggest that the downstream consequences of 
these protein interactions may be similar. 
  
4.3 Vpu mediates CD74 downregulation 
While knowledge of the exact binding site between Vpu and CD74 is beneficial, it 
is also important to understand the reasons why this interaction takes place. 
Although Vpu does not work alone, it is possibly one of the principal HIV-1 
proteins for immune evasion that has afforded the virus the ability to develop a 
more severe disease outcome compared to those strains lacking a functional Vpu 
protein. One of the mechanisms by which Vpu contributes to immune impairment 
is the downregulation and degradation of CD4, which has been described in 
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detail (Fujita et al., 1997; Schubert et al., 1998; Hill et al., 2010; Magadan et al., 
2010). The Vpu-mediated downregulation of CD4 has been corroborated within 
this study in untreated U937 cells (Figure 3.23, Table 3.1) – that were selected 
for these studies as they constitutively express both CD4 (Pelchen-Matthews et 
al., 1998) and CD74 (Zhou et al., 2011) – as determined by flow cytometry 
(Figure 3.23). This downregulation occurs within 24 hours post-transfection.   
 
The downregulation of MHCII through the interaction of Vpu with CD74 has also 
been previously reported (Hussain et al., 2008). Similar to that of CD4, this 
observation was also corroborated within this study (Figure 3.24). In this study, 
U937 cells were left untreated or treated with either PMA or IFN-γ 24 hours prior 
to transfection in order to determine if these factors also influence the levels of 
MHCII in both the presence and absence of Vpu. Total MHCII levels, including 
both intracellular and cell surface molecules, were significantly downregulated in 
the presence of Vpu regardless of the pre-treatment of the cells, and this was 
seen only at 24 hours post-transfection. This is contrary to what has been 
reported by another research group. Hussain and co-workers showed that MHCII 
levels were significantly downregulated in Vpu-transfected U937 cells at 24 hours 
at the cell surface only, while total MHCII levels that included intracellular 
molecules remained relatively unchanged by Vpu at this time point (Hussain et 
al., 2008). The difference between previously reported findings and those 
presented in this study may be due to the use of different subtypes of Vpu. 
Although the details of the Vpu plasmid and the method of transfection used are 
not specified for the flow cytometry analyses, it would seem that Hussain and co-
workers made use of subtype C Vpu as this subtype was used for other work 
within that particular study (Hussain et al., 2008), while subtype B Vpu was used 
within this study. Subtype B has been reported to localize mostly at intracellular 
membranes while subtype C is more commonly found at the plasma membrane 
(Bell, 2009; reviewed in Dubé et al., 2010a). It is possible that the different 
localization of these two subtypes may influence MHCII molecules within different 
compartments at different times during the infection cycle. Another possibility is 
that MHCII in U937 cells could be more concentrated at the cell surface and the 
inclusion of intracellular MHCII levels in the analysis may have had an 
insignificant effect. MHCII levels at 48 hours post-transfection were statistically 
similar between mock-transfected and Vpu-transfected cells (Table 3.2). It is 
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possible that the transient expression of Vpu in these cells may be reduced while 
normal protein expression would continue thus accounting for a natural increase 
in MHCII levels. 
  
The differential pre-treatment of cells yielded little to no variation in results on 
closer inspection of the mock-transfected cells, both at 24 and at 48 hours post-
transfection. The effects of both PMA and IFN-γ on U937 cells have been 
reported before (Celada and Maki, 1991; De Lerma Barbaro et al., 2005; Tosi et 
al., 2002). However these reports indicate conflicting data regarding the effect of 
PMA on the expression of MHCII levels within U937 cells. Celada and Maki 
reported that the MHCII I-A beta gene was not stimulated in macrophages by the 
treatment of PMA but was upregulated by IFN-γ (Celada and Maki, 1991), while 
Tosi et al. (2002) found that the PMA-treatment of U937 cells resulted in the 
differentiation of these cells to a macrophage-like phenotype and led to an 
increase in the levels and phosphorylation of the class II transactivator (CIITA). 
This ultimately causes an increase in the expression of MHCII molecules as 
CIITA is responsible for the regulation of MHCII expression (Tosi et al., 2002). 
Contrary to this, in a later study it was shown that CIITA and MHCII expression, 
in particular the HLA-DR molecule, is decreased in U937 cells after treatment 
with PMA, while IFN-γ did not have any effect on the levels of MHCII (De Lerma 
Barbaro et al., 2005). The difference between these two studies may be due to 
the different time points at which the levels of CIITA and MHCII were measured, 
as well as the different concentrations of PMA used. Within this thesis, U937 cells 
were treated with either PMA or IFN-γ for 24 hours before transfection and the 
activators were washed off. This may explain why no difference was seen in 
MHCII levels between untreated, PMA-treated and IFN-γ-treated cells (Table 
3.2). Perhaps, if cells had been treated for longer periods, differences in the 
MHCII levels may have been detected. Hussain et al. showed a decrease in 
MHCII in the presence of Vpu after the activation of U937 cells with 10 ng/μl of 
PMA (Hussain et al., 2008) and within this study, the cells were treated with 
double that concentration. However, it is possible that neither of these particular 
concentrations were sufficient to mediate an effect on MHCII expression. Future 
work may evaluate this more thoroughly. 
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The downregulation of MHCII occurs through the binding of Vpu to CD74 before 
the mature MHCII complex can reach the cell surface. It is possible that this 
occurs through the downregulation of CD74 itself, as this would prevent the 
maturation and peptide loading of MHCII. Within this study, we confirm the novel 
finding that CD74 is indeed downregulated through its interaction with HIV-1 Vpu 
and this occurs within a 24 hour time frame. This downregulation was indicated 
both via immunoprecipitation (Figure 3.22) as well as flow cytometry (Figure 3.25; 
Table 3.3). Statistical replicates indicated that CD74 levels were significantly 
reduced after Vpu transfection in untreated U937 cells only, but not in cells that 
were pre-treated with PMA or IFN-γ. The effect of PMA on MHC has been 
discussed above and while PMA was unable to induce the expression of CD74 
mRNA in keratinocytes (Freeman et al., 1998), it is not clear if PMA would have 
any effect on CD74 expression in U937 cells. Perhaps by halting MHCII 
expression through PMA treatment, total CD74 levels may increase rapidly as 
this protein would then not be incorporated into newly formed mature MHCII 
complexes, thereby overcoming downregulation via Vpu. However, there did not 
appear to be any notable difference in CD74 levels between untreated cells, 
PMA-treated cells and IFN-γ-treated cells in the mock-transfected samples (Table 
3.3). Despite this, it is possible that both PMA and IFN-γ have some effect on 
CD74 expression at 24 hours post-transfection. These treated cells were able to 
maintain CD74 levels consistent with those in mock-transfected cells, indicating 
that CD74 expression was high enough to overcome Vpu-mediated 
downregulation. At 48 hours post-transfection, all three sample types displayed a 
significant decrease in total CD74 levels. Possibly, at this time point the effect of 
the activators has been overcome and progeny cells may be expressing normal 
levels of CD74, which is then decreased in the presence of Vpu. 
  
While this specific data does not indicate CD74 degradation, it does indicate that 
total CD74 levels were downregulated in the presence of Vpu as whole cell lysate 
was used for immunoprecipitation, and cells were permeabilized prior to staining 
for flow cytometry, allowing for the measurement of total CD74 protein regardless 
of cellular location. Contrary to this, Hussain and co-workers indicated no 
significant decrease in cell surface CD74 levels in Vpu-EGFP-transfected U937 
cells 24 hours post-transfection (Hussain et al., 2008) and this has been 
attributed to the retention of CD74 within intracellular compartments (Patel et al., 
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2014). Within this work, total CD74 levels including surface and intracellular 
fractions were measured. It is possible that if the total levels of CD74 had been 
measured after transfection, as opposed to the cell surface levels only, within the 
Hussain study (Hussain et al., 2008), a difference in CD74 levels may have been 
seen. By investigating surface CD74 only, it is possible that Hussain and co-
workers were only analysing one or two of the CD74 isoforms. The p35 isoform 
has an ER retention signal within the cytoplasmic tail (Warmerdam et al., 1996; 
reviewed in Michelsen et al., 2005). Therefore this CD74 isoform may not have 
been included in the analysis. Another contemplation is that there may be a 
difference in the concentration of Vpu used to transfect the cells between the two 
studies. More efficient expression, or a greater concentration of Vpu present in 
the cells would lead to a more pronounced effect on the CD74 host protein. 
Finally, as with MHCII above, the difference in the reported results may be due to 
the use of different subtypes of Vpu. 
 
Analysis of total CD74 levels in cells expressing either of two Vpu 
phosphorylation mutants (Vpu-SM and Vpu-DM, respectively) resulted in CD74 
downregulation at 24 hours (Figure 3.26; Table 3.4). This suggests that Vpu does 
not mediate the proteasomal degradation of CD74 via the recruitment of β-TrCP, 
as both phosphorylated serines have been reported to be needed for the binding 
of β-TrCP in order to recruit the E3 ligase complex (Bour et al., 1995; Paul and 
Jabbar, 1997). However, it is still possible that Vpu mediates CD74 degradation 
through the ERAD pathway, as this viral protein has been reported to target both 
CD4 (Magadan et al., 2010) and tetherin (Mangeat et al., 2009) via ERAD in 
addition to β-TrCP-dependent degradation. A further consideration is that Vpu 
may be capable of downregulating CD74 through altering CD74 gene expression. 
Vpu has recently been observed to impede NF-κB-related antiviral gene 
expression (Sauter et al., 2015). Vpu mutants lacking both the phosphorylated 
serines at position 52 and 56 were equally capable of downregulating antiviral 
gene expression (Sauter et al., 2015), indicating that the phosphorylated serines 
are not required for this function. At 48 hours post-transfection, CD74 levels are 
downregulated significantly by the double phosphorylation mutant (Vpu-DM), but 
not by the single mutant (Vpu-SM), in which total CD74 levels were statistically 
equivalent to the mock-transfected cells (Table 3.4). This difference in CD74 
levels between the 24 hour and 48 hour Vpu-SM-transfected samples may be 
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due to the degradation of the Vpu-SM protein at 48 hours post-transfection. As 
mentioned previously, Vpu itself undergoes proteasomal degradation due to the 
phosphorylation of the serine residue at position 61 (Estrabaud et al., 2007). Vpu 
proteins that have a mutation at both Ser52 and Ser56 are not degraded in this 
way, indicating that these two conserved residues are required for Vpu 
ubiquitination and degradation, along with the phosphorylated Ser61 residue 
(Belaϊdouni et al., 2007; Estrabaud et al., 2007). However, Vpu proteins 
containing a mutation of only one of the phosphorylated serines were not 
analysed for degradation during these studies (Belaϊdouni et al., 2007; Estrabaud 
et al., 2007) and it is possible that the presence of a phosphorylated serine at 
position 56 and at 61 in combination allows for the recognition of Vpu as a target 
protein for degradation. The single mutant (Vpu-SM) used in this study only had 
Ser52 replaced with alanine, but still contained Ser56. It is possible that this 
mutant became phosphorylated at Ser61 and had been degraded by the 48 hour 
time point. This would allow for normal CD74 expression to resume.  
 
Although Hussain and co-workers also demonstrated reduced levels of MHCII 
and no reduction in CD74 levels in virus-infected cells (Hussain et al., 2008), this 
data is incomparable to the work presented here as there are additional HIV-1 
viral proteins that are involved in the downregulation of MHCII and that are 
reported to interact with CD74. These include the Nef accessory protein and the 
gp41 protein. HIV-1 Nef interferes with both CD74 and MHCII as it 
downmodulates MHCII by increasing CD74 at the cell surface, and by 
upregulating cell surface expression of immature MHCII. Nef is also capable of 
decreasing the surface levels of mature, peptide-loaded MHCII (Stumptner-
Cuvelette et al., 2001; reviewed in Kirchhoff, 2010; Ghiglione et al., 2012). HIV-1 
gp41 has also been shown to interact with cell surface CD74 early in infection, 
causing the modulation of the ERK/MAPK pathway in order to enhance viral 
infections (Zhou et al., 2011). The interaction of these other viral proteins with 
CD74 and the effect that this would have on MHCII production may have 
influenced the data obtained from virus-infected cells.  
 
4.4 Further considerations 
While the present study gives insight not only to the specific binding interaction 
between Vpu and CD74, but also to the downstream consequences of this 
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interaction, there are further aspects that could be considered in future studies. 
This study could be repeated in a different cell line to determine if the same data 
would be generated. An NMR structure for CD74 has previously been described 
(Motta et al., 1995) but no three dimensional crystal structures have as yet been 
uploaded on the PDB for the cytoplasmic domain in particular. A three 
dimensional structure of the CD74 cytoplasmic domain with co-ordinates 
uploaded to the PDB would greatly aid in the investigation of the specific binding 
site between CD74 and Vpu. This would allow for the “hot spot” residues in the 
interaction to be identified using in silico modelling. In conjunction with this, the 
specific binding site between Vpu and CD74 could be confirmed using a different 
technique such as CSP, as previously described for the interaction between Vpu 
and CD4 (Singh et al., 2012). This would most likely result in a clearer indication 
of the residues involved in the interaction as this technique also allows for the 
secondary structure of each protein to be taken into consideration, and this may 
also influence the binding sites. This particular technique would also allow for the 
investigation of which residues are involved in binding while using full-length 
proteins that are correctly folded. Further to this, in vitro assays that mimic a 
membrane environment might also be considered. For example, the inclusion of 
DPC micelles within the assay would also allow for the correct folding of each 
peptide. This may be used with the overlapping peptide sets (described in 
Chapter 2) to overcome the difficulty of possible differences in folding for each 
small peptide in an aqueous buffer system. 
  
In addition, studies investigating the existence of a Vpu/CD74/β-TrCP ternary 
complex would complement the work presented here. The discovery of this 
complex, should it exist, would lend to the description of Vpu-mediated CD74 
degradation and would indicate the type of degradation. This is because β-TrCP 
is involved in the recruitment of the E3 ubiquitin ligase complex through 
interaction with the Skp1p factor (Margottin et al., 1998). Therefore the existence 
of the Vpu/CD74/β-TrCP ternary complex would suggest that by binding with 
Vpu, CD74 becomes ubiquitinated after the recruitment of β-TrCP and the E3 
ligase complex. Once ubiquitinated, CD74 would then be degraded via the 26 S 
proteasome (Tu et al., 2012). This investigation could be taken one step further 
by the discovery of an ubiquitinated form of CD74 after either infection of cells by 
HIV-1 or transfection with Vpu. Furthermore, the effects of a proteasome inhibitor, 
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such as MG132, on the degradation of CD74 could also be investigated. This 
would serve as a confirmatory assay. 
Following the confirmation of the specific binding sites and further delineation of 
the downregulation or possible degradation of CD74, the inhibition of this 
interaction should be considered. The information regarding the specific binding 
site detailed within this study will contribute to the design of drug molecules 
targeting this interaction. Furthermore, structural details of the binding sites would 
allow for the design of compounds as potential inhibitors using in silico modelling. 
This would be aided by the knowledge of the three dimensional structure of the 
CD74 cytoplasmic domain. Once synthesized, these compounds could then be 
screened using a functional inhibition assay. There is already evidence to support 
Vpu as a suitable drug target. This is indicated by the BIT225 candidate drug, 
which was found to block the ion channel activity of Vpu specifically. BIT225 also 
has been found to have anti-HIV-1 activity within macrophages and has been 
reported to have very low cell toxicity (Khoury et al., 2010). This candidate drug 
was discovered through the exploration of amiloride analogues that were capable 
of inhibiting the flow of ions through the Vpu ion channel (Ewart et al., 2002). 
BIT225 was shown to be ineffective against HIV-2 which lacks a functional Vpu 
protein, indicating that the drug target is specific to HIV-1 Vpu (Khoury et al., 
2010) and affects the viroporin activity of HIV-1 Vpu without mediating an effect 
on the Vpu/tetherin interaction (Kuhl et al., 2011). This same approach could be 
followed for the design and analysis of potential inhibitors of the Vpu/CD74 
interaction. Alternatively, inhibitors of the Vpu immunodominant domain indicated 
within this study could be designed as CD74 binds to this region. Any compound 
or molecule that prevents the binding of the anti-Vpu antibody would then most 
likely bind to the same region as CD74. 
  
Finally, once HIT compounds have been found and developed, they could be 
tested in an animal model in order to investigate the efficacy of these possible 
drug compounds to determine the modulation, if any, of this disease. 
 
4.5 Concluding remarks 
This study undertook the description of the Vpu/CD74 interaction and details the 
downstream consequences following the binding of these two proteins. Using in 
vitro assays, it was confirmed that CD4 and CD74 compete for binding to Vpu, 
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despite inducing different responses. This work provides novel information on the 
definitive protein-protein binding site between HIV-1 Vpu and the host protein 
CD74. Furthermore, the deleterious effect of HIV-1 Vpu on host cell immunity has 
been indicated within this study through the novel finding of the Vpu-mediated 
downregulation of CD74 in U937 cells. However, CD74 is not targeted for 
degradation in a mechanism similar to that of CD4 through binding HIV-1 Vpu. 
 
CD74 was able to prevent the binding of an anti-Vpu antibody, most likely by 
binding to an immunodominant domain on Vpu. The binding site between these 
proteins was identified and the specific residues involved were 
RIRERAEDSGNESEG and EDQKP within the Vpu and CD74 cytoplasmic 
domains, respectively. In addition to this, it was shown that steric hindrance may 
be a determining factor in the binding interaction between these two proteins. 
Moreover, total CD74 levels in U937 cells were downregulated both at 24 and 48 
hours post-transfection with Vpu under normal conditions. Finally, two Vpu 
phosphorylation mutants were also found to cause downregulation of total CD74 
levels at 24 hours under normal conditions, suggesting that Vpu does not 
mediate the degradation of CD74 through traditional recruitment of the E3 ligase 
complex. 
 
Considering the wide variety of roles that CD74 plays within a cell, both in cell 
signalling and in the functioning of the immune system, it is important for this host 
protein to be able to continue to function. Therefore CD74 is an attractive host 
target for HIV-1 and inhibition of the interaction between Vpu and CD74 may be 
disadvantageous for viral persistence. In view of this, the targeting of this 
particular HIV-1 accessory protein would greatly aid in the modulation of this 
disease.  
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Appendix B 
Table A.1: Absorbance (A650) values for all ELISA data recorded in the Results chapter, indicating which peptides were coated/plated and which were 
incubated with the plated peptides. For Vpu, only Vpu::GFP (full length protein) and the responsive, numbered Vpu peptides are indicated. Key: black – 
anti-Vpu, subtype B (NIH); blue – anti-Vpu, subtype C (NIH); red – anti-Vpu (Abcam); green – anti-GFP; purple – anti-CD4; pink – anti-CD74. Orange 
bars indicate intensity of response. NA – not applicable. 
 
60min Vpu #10 (B) Vpu #13 (B) Vpu #10 (C) Vpu #11 (C) Vpu #18 Vpu #19 Vpu::GFP Vpu::GFP Vpu::GFP Vpu::GFP
Antibodies only 0.848 0.496 0.503 1.034 1.254 0.764 0.784 0.691 0.176 0.168
CD4 (FLP) 1.131 0.564 0.952 1.263 NA NA 0.507 NA 1.370 NA
CD74 (FLP) 0.207 0.106 0.069 0.319 NA NA 0.144 0.693 NA 1.844
CLIP 0.804 0.485 0.402 0.912 NA NA 0.959 NA NA NA
CD74_10mer1 1.034 0.769 NA NA 1.490 0.878 0.564 NA NA NA
CD74_10mer2 0.857 0.642 NA NA 1.733 0.815 0.497 NA NA NA
CD74_10mer3 0.804 0.613 NA NA 1.579 0.744 0.512 NA NA NA
CD74_10mer4 0.783 0.599 NA NA 1.517 0.713 0.518 NA NA NA
CD74_10mer5 0.826 0.566 NA NA 1.234 0.734 0.585 NA NA NA
CD74_15mer1 1.185 0.154 NA NA 1.098 0.808 0.449 NA NA NA
CD74_15mer2 1.096 0.174 NA NA 1.364 0.769 0.683 NA NA NA
CD74_15mer3 1.036 0.181 NA NA 1.350 0.719 0.652 NA NA NA
CD74_15mer4 1.037 0.176 NA NA 1.419 0.669 0.627 NA NA NA
Combo 2 NA NA NA NA NA NA 0.073 NA NA NA
Combo 3 NA NA NA NA NA NA 0.067 NA NA NA
Combo 4 NA NA NA NA NA NA 0.065 NA NA NA
Combo 5 NA NA NA NA NA NA 0.063 NA NA NA
Antibody only 0.075 0.071 NA 0.075 NA NA NA NA NA NA
CD4 (FLP) 1.362 1.344 NA 1.390 NA NA NA NA NA NA
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Plated
